FUNDING NEWSLETTER APRIL 2014 NIH NOTICES

Transcription

FUNDING NEWSLETTER
APRIL 2014
Notice of Intent to Publish a Funding Opportunity
Announcement for Centers of Cancer
Nanotechnology Excellence (U54) (NOT-CA-14033)
Notice of National Cancer Institute (NCI)
Participation in PA-14-156 "Extended
Development, Hardening and Dissemination of
Technologies in Biomedical Computing,
Informatics, and Big Data Science (R01)" (NOTCA-14-041)
National Cancer Institute
"http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14033.html"
Notice of National Cancer Institute's Interest in
Supporting Cancer Nanotechnology Research
Training Programs (NOT-CA-14-035)
Notice of Agency Decision: The Density of the
Primary Living Space of Captive Chimpanzees
Owned or Supported by the NIH or Used in NIHSupported Research (NOT-OD-14-051)
NIH NOTICES
Notice of Expiration of PAR-14-013 "Early Phase
Clinical Trials in Imaging and Image-Guided
Interventions (R21)" (NOT-CA-14-036)
Announcement for Cancer Nanotechnology
Research Platforms (U01) (NOT-CA-14-037)
Announcement for the Physical SciencesOncology Network (PS-ON): Physical SciencesOncology Projects (PS-OP) (U01) (NOT-CA-14-039)
Notice of National Cancer Institute (NCI)
Participation in PA-14-155 "Early Stage
Development of Technologies in Biomedical
Computing, Informatics, and Big Data Science
(R01)" (NOT-CA-14-040)
SCCC Research Administration
National Institutes of Health
"http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14051.html"
NIH Will Open the Research Performance
Progress Report (RPPR) for All Type 5 Non-SNAP
Progress Reports on April 25, 2014 (NOT-OD-14064)
Notice of Online Data Submission and Access to
the National Institutes of Health (NIH) database of
Genotypes and Phenotypes (dbGaP) (NOT-OD-14065)
Notice of Reissuance of the Ruth L. Kirschstein
National Research Service Award (NRSA)
Individual Fellowship Funding Opportunity
Announcements (NOT-OD-14-066)
Request for Information: Invitation to Comment
on Proposed Guidance Regarding Significant
Changes to Ongoing Animal Activities (NOT-OD14-063)
April 2014 Funding Newsletter
Page 1 of 49
Adjustments to May 25-28, 2014 Grant Application
Due Dates (NOT-OD-14-070)
NIH Extramural Grant Systems Upgrade for
Unicode Compatibility Means Memorial Day
Weekend Downtime (NOT-OD-14-071)
Request for Information (RFI): Availability of Data
and Samples from Randomized Smoking
Cessation Trials (NOT-DA-14-005)
"http://grants.nih.gov/grants/guide/notice-files/NOT-DA-14005.html"
Maintaining Confidentiality in NIH Peer Review
(NOT-OD-14-073)
APRIL DEADLINES
Foundation and Other Sources
Association for International Cancer Research
(AICR)
Research Grants
April 25, 2014
Application Due Date:
"http://www.aicr.org.uk/applyingforagrant.stm"
About
AICR awards project grants of between one and three
years to support fundamental and translational research
into the causes, mechanisms, diagnosis, treatment and
prevention of cancer.
Period of Support
Funds/Direct Costs
Program Contact
Up to 3 years
AICR does not have a formal upper
limit for project budgets
AICR
enquiries@aicr.org.uk
Bladder Cancer Advocacy Network (BCAN)
Bladder Cancer Research Innovation Award
February 12, 2014
Letter of Intent Due Date:
April 23, 2014
"http://www.bcan.org/research/grants/bladder-cancerresearch-innovation-award/"
About
The application process is now open for BCAN’s Bladder
Cancer Research Innovation Award. BCAN is pleased to
announce this award, which will support the work of one
investigator with an exceptionally novel and creative project
with great potential to produce a breakthrough in the
management of bladder cancer. Letters of Intent (LOI) are
required and are due by February 12, 2014. Selected
applicants will be chosen to submit full proposals. If invited,
full proposals are due by April 23, 2014.
Period of Support
Funds/Direct Costs
Program Contact
2 years
$300,000 total costs over entire
period of support
Bladder Cancer Advocacy Network
(BCAN)
grants@bcan.org
Margaret Q. Landenberger Research Foundation
Research Grant
University of Miami Internal
Review Deadline:
February 14, 2014
April 15, 2014
About
The Margaret Q. Landenberger Research Foundation (“the
Foundation”) is a non-profit private foundation which
focuses its support on promising, early stage medical
researchers. The ideal candidate is affiliated with an
outstanding medical research institution and works under
the supervision of experienced mentors. Our goal is to
assist these individuals by funding their current research,
with the hope of enabling them to acquire more significant
funding. We do not restrict our support to any particular
disease or medical condition. Since the University of Miami
may only submit one proposal, this opportunity is a limited
submission competition. The internal application deadline is
February 14, 2014. An expert panel will internally review
our candidates to determine which application will be
submitted for competition by the Margaret Q. Landenberger
Research Foundation deadline on April 15, 2014.
2 years
Period of Support
Funds/Direct Costs $100,000 direct costs per year
Karen Del Rio
Internal Contact
kdelrio@miami.edu
Multiple Myeloma Research Foundation
Research Fellow Award
April 22, 2014
"http://www.themmrf.org/research-programs/for-academicresearchers/grant-opportunities.html#fellows"
About
The Multiple Myeloma Research Foundation (MMRF)
seeks proposals for the Research Fellow Award Program,
an initiative supporting researchers with less than five years
experience (post graduate degree) working under the
supervision of a research mentor in the multiple myeloma
field. The goal of this initiative is to help support young
Page 2 of 49
investigators studying in the field of multiple myeloma while
advancing the understanding of myeloma disease biology,
treatment and drug resistance.
Up to 1 year
Period of Support
Funds/Direct Costs $75,000 total costs for 1 year
Up to 10% indirect costs are allowed
Budgetary Notes
Program Contact Mariadora Saladino, MPA
(203) 229-0464
info@themmrf.org
Request for Applications (RFA)
Multiple Institutes, including the National Cancer
Institute
Empirical Research on Ethical Issues Related to
Central IRBs and Consent for Research Using
Clinical Records and Data (R01)
RFA-OD-14-002
April 18, 2014
"http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-14002.html"
About
The purpose of this Funding Opportunity Announcement
(FOA) is to encourage Research Project Grant (R01)
applications to explore two timely issues of significance for
policy development relevant to: 1) the principles and
characteristics for central Institutional Review Boards
(IRBs); and 2) consent and participant preferences for
research using clinical records and data. This FOA utilizes
the NIH (R01) Research Project Grant award mechanism.
Period of Support
Funds/Direct Costs
Program Contact
Up to 3 years
Application budgets are not limited
but need to reflect the actual needs
of the proposed project
Clarlisse Caga-Anan
(240) 276-6738
charlisse.caga-anan@nih.gov
Institute
Bridge Awards to Accelerate the Development of
Cancer Therapeutics, Imaging Technologies,
Interventional Devices, Diagnostics & Prognostics
(R44)
RFA-CA-14-002
April 21, 2014
"http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-14002.html"
About
The National Cancer Institute (NCI) invites applications for
Small Business Innovation Research (SBIR) applications
from small business concerns (SBCs) that seek additional
funding to support the next stage of development for
projects that were previously funded by NIH SBIR Phase II
awards. Projects proposed in response to this FOA must be
applicable to one of the following areas: (1) cancer
therapeutics; (2) cancer imaging technologies,
interventional devices, and in vivo diagnostics; or (3) in vitro
and ex vivo cancer diagnostics and prognostics. This FOA
will utilize the NIH (R44) Small Business Innovation
Research (SBIR) Grant - Phase II only.
3 years
Period of Support
Funds/Direct Costs $3M total costs per year
Program Contact Andrew J. Kurtz
(240) 276-5228
kurtza@mail.nih.gov
MAY/JUNE DEADLINES
Florida Department of Health
Florida Translational Research Program Awards
Deadline: May 29, 2014
"http://www.sanfordburnham.org/technology/centers/cpccg/fl
oridatranslationalresearchprogram/Pages/ProgramDescription.aspx"
About
The purpose of the Florida Translational Research Program
(FTRP) is to produce a pipeline of potential new medicines
based upon laboratory research discoveries. The Program
provides Florida-based scientists with access to
experienced professionals and state-of-the-art
technological resources for drug discovery to facilitate an
interdisciplinary, collaborative approach to the
establishment of a pipeline of potential new treatments for
today’s most challenging and unmet medical needs. The
Program is funded by the state of Florida through the
Florida Department of Health and is administered and
performed by Sanford-Burnham Medical Research Institute
at Lake Nona. The goals of the FTRP are to implement a
variety of innovative biochemical and cell-based assays to
interrogate biological targets or processes for which there
are limited selective and potent small-molecule modulators
available; to execute high-throughput screens; and to
develop lead compounds suitable for use in vivo.
Page 3 of 49
Period of Support Unspecified
Funds/Direct Costs There is no transfer of funds
associated with selection of projects,
successful applicants will obtain
access to resources that can be
applied to the discovery and
development of innovative chemical
tools for use in biological research
Program Contact Florida Translational Research
Program
ftrp@sanfordburnham.org
Ovarian Cancer Research Fund, Inc.
Program Project Development Grant
May 6, 2014
"http://www.ocrf.org/ovarian-cancer-research/ourgrantees/program-project-development-grant"
About
The purpose of this program is to provide funds for ovarian
cancer research that may involve several investigators
within one institution or collaborations between groups in
multiple institutions.
Period of Support 3 years
Funds/Direct Costs Up to $300,000 direct costs per year
Budgetary Notes No indirect costs allowed
Program Contact Sarah DeFeo
(212) 268-1002
grants@ocrf.org
Elsa U. Pardee Foundation
Research Grants
Deadline: June 1, 2014
"http://www.pardeefoundation.org/grants.aspx"
About
The Elsa U Pardee Foundation funds research directed
toward identifying new treatments or cures for cancer. The
sponsor particularly encourages grant applications for a
one year period which will allow establishment of
capabilities of new cancer researchers, or new cancer
approaches by established cancer researchers. Project
relevance to cancer detection, treatment, or cure should be
clearly identified.
Period of Support Up to 1 year
Funds/Direct Costs Unspecified
Budgetary Notes Applications requesting more than
twenty-five percent overhead are
usually not considered
Program Contact Elsa U. Pardee Foundation
P.O. Box 2767
Midland, MI 48641-2767
(989) 832-3691
kmcdonald@pardeefoundation.org
Department of Defense
Breast Cancer Research Program (BCRP)
Breakthrough Award Levels 3 and 4
Preliminary Application Due: May 14, 2014
August 15, 2014
"http://cdmrp.army.mil/funding/pa/14bcrpbreakthrough34_pa
.pdf"
About
The intent of the Breakthrough Award is to support
promising research that has high potential to lead to or
make breakthroughs in breast cancer. The critical
components of this award mechanism are: --Impact:
Research supported by the Breakthrough Award will have
the potential for a major impact and accelerate progress
toward ending breast cancer. The impact may be near-term
or long-term, but must be significant and move beyond an
incremental advancement. Applications must articulate the
pathway to making a clinical impact for individuals with, or
at risk for, breast cancer, even if clinical impact is not an
immediate outcome. --Research Scope: Research
proposed under this award mechanism may be small- to
large-scale projects, at different stages of idea and
research development. Pre-applications are required and
must be received by May 14, 2014. The sponsor will invite
selected applicants to submit full proposals. If invited, full
proposals must be received by August 15, 2014.
Funds/Direct Costs Level 3 funding: $2.5M direct costs
for the entire period of support;
Level 4 funding: $10M direct costs
for the entire period of support
Program Contact Congressionally Directed Medical
Research Program
(301) 682-5507
help@cdmrp.org
L’Oréal USA
L’Oréal For Women in Science Fellowship Program
May 19, 2014
"www.lorealusa.com/forwomeninscience"
About
The L’Oréal USA For Women In Science fellowship
program will award five post‐doctoral women scientists in
the United States this year with grants of up to $60,000
each. Applicants are welcome from a variety of fields,
including the life and physical/material sciences, technology
(including computer science), engineering, and
mathematics.
Period of Support One-time award
Funds/Direct Costs Up to $60,000 total costs for onetime award
Program Contact Myriam Coneim
mconeim@us.loreal.com
Page 4 of 49
B*CURED
Research Grant
June 1, 2014
"http://bcured.org/for-researchers/"
About
B*CURED’s primary goal is to fund innovative brain cancer
research. Grants are presented annually by B*CURED to
Assistant Professors/ Instructors whose research proposals
demonstrate the highest chance of generating novel,
meaningful data that will ultimately lead to an NIH-funded
research program dedicated to a cure for malignant brain
tumors.
Funds/Direct Costs $50,000 total costs for one-time
award
Program Contact B*CURED
(203) 869-6048
research@bcured.org
NEW
Call for Applications: Alex's Lemonade Stand
Foundation
Bio-Therapeutics Impact Award
June 12, 2014
"http://www.alexslemonade.org/grants/programareas/accelerator-programs"
About
The Bio-Therapeutics Impact Award accelerates the
development of clinical trials for promising biologic
approaches to treating childhood cancer. These
approaches include, but are not limited to, immunotherapy,
gene therapy and small molecules. The award is intended
for investigators who are initiating clinical trials or
undertaking the pre-clinical work necessary to move into
the IND (investigational new drug) phase.
Funds/Direct Costs Up to $1.5M total costs for entire
period of support
Program Contact Jenny Filer
(610) 649-3034
grants@alexslemonade.org
Patient-Centered Outcomes Research Institute
(PCORI)
Improving Methods for Conducting PatientCentered Outcomes Research
March 7, 2014
May 6, 2014
"http://www.pcori.org/funding-opportunities/fundingannouncements/improving-methods-for-conducting-patientcentered-outcomes-research-spring-2014-cycle/"
About
In this PCORI Funding Announcement (PFA), the
Improving Methods for Conducting Patient - Centered
Outcomes Research program seeks projects to address
gaps in methodological research relevant to conducting
PCOR. Results of these projects will inform future
iterations of The PCORI Methodology Report. The
improvement of existing methods will benefit all
stakeholders, including researchers planning
investigations, policy makers weighing the value of
healthcare interventions; and patients, clinicians, and
caregivers facing healthcare decisions. Letters of intent are
required and due by March 7, 2014. Selected applicants
will be chosen to submit full proposals. If invited, full
proposals are due by May 6, 2014.
Period of Support Up to 3 years
Program Contact PCORI
pfa@pcori.org
(PCORI)
Communication and Dissemination Research
Program
March 10, 2014
May 6, 2014
"http://www.pcori.org/funding-opportunities/fundingannouncements/communication-and-disseminationresearch-spring-2014-cycle/"
About
PCORI invites applications for projects that address critical
knowledge gaps in the communication and dissemination
process, both the communication and dissemination of
research results to patients, their caregivers, and clinicians,
as well as the communication between patients, caregivers,
and clinicians in the service of enabling patients and
caregivers to make the best possible decisions in choosing
among available options for care and treatment. Letters of
intent are required and due by March 10, 2014. Selected
applicants will be chosen to submit full proposals. If invited,
full proposals are due by May 6, 2014.
(202) 627-1884
pfa@pcori.org
(PCORI)
Effectiveness of Transitional Care
March 10, 2014
May 6, 2014
"http://www.pcori.org/funding-opportunities/fundingannouncements/the-effectiveness-of-transitional-care/"
Page 5 of 49
About
PCORI is soliciting applications for research to determine
which transitional care service clusters are most effective in
improving patient-centered outcomes while optimizing readmission rates in different at-risk subpopulations and in
different healthcare contexts (e.g., fee-for-service,
capitation, new payment models, medical homes, and
integrated delivery systems). Letters of intent are required
and due by March 10, 2014. Selected applicants will be
chosen to submit full proposals. If invited, full proposals due
by May 6, 2014.
Funds/Direct Costs $15M total costs over entire period
of support
pfa@pcori.org
(PCORI)
Improving Healthcare Systems
March 10, 2014
May 6, 2014
"http://www.pcori.org/funding-opportunities/fundingannouncements/improving-healthcare-systems-spring2014-cycle/"
Pediatric Cancer Research Foundation (PCRF)
Designated Grant Program
May 1, 2014
"http://www.pcrfkids.org/site/c.bjJULdNRJkL4H/b.8483009/k.95B0/Grant_Le
vels.htm"
About
Funds projects in communities or regions local to the
specific donor or fundraising activity. Outside contributing
organizations, fundraisers and donors work with the
Foundation to identify a specific project, focus on a specific
disease type, facility or awareness program.
Period of Support 1 year, can be renewed annually
Budgetary Notes Indirect costs are not allowed
Program Contact Jeri Wilson
jwilson@pcrf-kids.org
High Impact Grant
May 1, 2014
vels.htm"
About
The Improving Healthcare Systems (IHS) program within
the Patient-Centered Outcomes Research Institute
(PCORI) invites applications for research comparing the
effectiveness of innovative features of health cares systems
e.g., innovative technologies, incentives and/or personnel
deployments intended to optimize the quality, outcomes,
and/or efficiency of care for the patients they serve.
Healthcare systems are composed of many components
and processes, including private and public health
insurance plans; physician groups; hospitals, nursing
homes, and assisted living facilities; academic medical
centers; integrated delivery systems; community-based and
safety-net clinics; federal, state, and municipal providers;
and other entities organized to deliver, improve, arrange,
purchase, or coordinate health care services. PCORI seeks
studies that will provide valuable knowledge to patients,
their caregivers, and clinicians, as well as to healthcare
leaders, regarding which features of systems lead to
improved outcomes that are important to patients and their
families. Letters of intent are required and due by March
10, 2014. Selected applicants will be invited to submit full
proposals. If invited, full proposals are due by May 6, 2014.
About
These grants are designed to fill the critical need for startup funds for young researchers to pursue exciting research
ideas. Because grant funds are scarce, it is difficult for
those early in their careers to compete with more
established researchers. These grants keep new
researchers focused on childhood cancer. These grants
are for scientists focused on innovative research offering
the greatest potential to design treatments and improve
outcomes for children with difficult-to-treat cancers. These
grants encourage and cultivate the best and brightest
researchers of the future and may lead to long term
commitments to research projects.
Funds/Direct Costs Up to $5M direct costs per year
pfa@pcori.org
May 1, 2014
vels.htm"
Period of Support 1 year, can be renewed annually
Funds/Direct Costs Up tp $75,000 direct costs per year
Translation Research Grant
About
This grant primarily funds new research protocols and
therapies that hold promise for improved outcomes and
accelerates cures from the laboratory bench to the bedside
of children and teens with high-risk cancers. This Grant will
be given to a program that involves open, multi-institutional
cancer clinical trials, or consortia, and implements new
Page 6 of 49
approaches to therapy.
Period of Support Multiple years
Society of Interventional Radiology Foundation
Harvey L. Neiman Health Policy Institute
Cost-Effectiveness and Quality Outcomes
Research Grant
June 1, 2014
"http://www.sirfoundation.org/grants-awards/"
About
The Cost-Effectiveness and Quality Outcomes Research
Grant is designed to fund research evaluating the cost, costeffectiveness, and quality and outcomes of interventional
radiology interventions and treatment approaches in
comparison to other established and emerging treatments.
These grants should emphasize observational studies and
secondary data analyses evaluating the use of image
guided minimally invasive therapies in real-world settings.
The research from these studies would provide health care
providers, patients, health insurers, and policy makers with
additional information upon which to base decisions
concerning the incorporation of these procedures into an
integrated healthcare system. Applicants should propose
research that advances the field of interventional radiology
and evaluates the cost, cost-effectiveness, and quality
outcomes of IR interventions.
Funds/Direct Costs Up to $30,000 total costs
Program Contact Society of Interventional Radiology
(800) 488-7284
American Society of Hematology (ASH)
Junior Faculty Scholar Awards
May 7, 2014
August 1, 2014
"http://www.hematology.org/Awards/Scholar/2407.aspx"
About
The American Society of Hematology (ASH) Scholar
Awards are designed to support hematologists who have
chosen a career in research by providing partial salary or
other support during that critical period required for
completion of training and achievement of status as an
independent investigator. Letters of Intent (LOI) are
required and due by May 7, 2014. Applications will be
made available to applicants who successfully submit LOI
by the deadline on June 5, 2014. Full applications are due
by August 1, 2014.
Funds/Direct Costs $75,000 total costs per year
Budgetary Notes Up to 15% of the award can be (but is
not required to be) used for benefits,
including medical and dental insurance,
life insurance and retirement benefits
Program Contact ASH
(202) 776-0544
awards@hematology.org
North American Neuroendocrine Tumor Society
(NANETS)
Young Investigator Award
June 30, 2014
"http://www.nanets.net/research/2014-young-investigatoraward-criteria"
About
The purpose of the NANETS Young Investigator Award is
to encourage investigators at the end of their fellowship or
beginning of their faculty appointment to pursue basic
and/or translational research focused on neuroendocrine
tumors. Candidates must be in the first 5 years of a faculty
appointment (instructor, research scientist or above) in an
accredited medical school or other institution in North
America and must be a NANETS members.
Period of Support 1 year
Program Contact NANETS
(360) 314-4112
American Institute For Cancer Research
Investigator Initiated Grants
January 27, 2014
May 12, 2014
"http://www.aicr.org/research/grant/research_funded_grant_
programs.html"
About
The American Institute for Cancer Research (AICR) Grant
Program is dedicated to funding research on cancer
prevention, treatment and survival through food, nutrition,
physical activity and weight management. This program
aims to increase understanding of the cancer process,
including cancer initiation, promotion, progression and
metastasis. Letters of Intent (LOI) are required and due by
January 27, 2014. Selected applications will be invited to
submit full proposals, if invited, full proposals are due by
May 12, 2014.
Period of Support Up to 2 years; 3 years for special start
up grants
Funds/Direct Costs $75,000 per year direct costs
Budgetary Notes 10% indirect costs are allowed
Program Contact Research Department
(202) 328-7744
aicrweb@aicr.org
Page 7 of 49
Liz Tilberis Early Career Award
May 6, 2014
"http://www.ocrf.org/wp-content/uploads/2015-Tilberis-LOIRFP.pdf"
About
The Liz Tilberis Scholars Program is directed towards junior
faculty with a strong commitment to an investigative career
in the field of ovarian cancer research. The intent of these
awards is to support a substantial time commitment to
research and academic endeavors in ovarian cancer.
Funds/Direct Costs $150,000 direct costs per year for 3
years
(212) 268-1002
grants@ocrf.org
American Institute for Cancer Research
Matching Grants
January 27, 2014
May 12, 2014
"http://www.aicr.org/research/grant/research_funded_grant_
programs.html"
About
The American Institute for Cancer Research (AICR) Grant
Program is dedicated to funding research on cancer
prevention, treatment and survival through food, nutrition,
physical activity and weight management (body fatness).
This program aims to increase understanding of the cancer
process, including cancer initiation, promotion, progression
and metastasis. AICR is interested in working with for-profit
corporations and/or not-forprofit organizations in funding
cancer research consistent with AICR’s areas of interest.
Letters of Intent (LOI) are required and due by January 27,
2014. Selected applications will be invited to submit full
proposals. If invited, full proposals are due by May 12, 2014.
Period of Support Not specified
Funds/Direct Costs $75,000 total direct costs
Program Contact Research Department
(202) 328-7744
research@aicr.org
Program Contact Doctors Cancer Foundation
dcf@doctorscancerfoundation.org
Lung Cancer Research Foundation (LCRF)
Research Grants
June 16, 2014
"http://www.lungcancerresearchfoundation.org/ourresearch/current-grants/"
About
Grants are awarded for lung cancer projects focused on:
basic science, translational research, clinical research,
supportive care, and quality of care/outcomes. Grant
requests can include new project submissions as well as
requests for renewal of current funding. The submissions
are evaluated according to the standard NIH guidelines for
scientific merit and originality of concept by the Medical
Advisory Board of LCRF.
Program Contact LCRF
(212) 588-1580
grants@lungfund.org
Children’s Leukemia Research Association
Research Grant Program
June 30, 2014
"http://www.childrensleukemia.org/researchgrants.html"
About
The sponsor funds research grants for investigators who
are conducting the most promising research into leukemia,
in the hopes of isolating the causes and finding a cure for
this disease.
Program Contact Research Grant Department
(516) 222-1944
info@childrensleukemia.org
Innovator Award
Doctors Cancer Foundation
Research Grant
May 31, 2014
"http://doctorscancerfoundation.org/id4.html"
August 15, 2014
"http://cdmrp.army.mil/funding/pa/14bcrpinnov_pa.pdf"
About
The sponsor provides support for the best program for the
management of cancer. There is a strong interest in cancer
stem cells, microRNAi agents, epigenetic agents, as well as
many others. The sponsor is particularly interested in
promoting the best of the young scientists. The project
should be innovative, sound and be able to lead to clinical
trials.
About
The Innovator Award supports visionary individuals who
have demonstrated creativity, innovative work, and
leadership in any field including, but not limited to, breast
cancer. The Innovator Award will provide these individuals
with the funding and freedom to pursue their most novel,
visionary, high-risk ideas that could ultimately lead to
ending breast cancer. The PI must commit at least 50% of
Page 8 of 49
his/her full-time professional effort during the award period
to breast cancer research. Preliminary applications are due
by May 14, 2014. The sponsor will invite selected
applicants to submit full proposals. If invited, full
applications are due by August 15, 2014.
Funds/Direct Costs $5M direct costs for entire period of
support
Program Contact Congressionally Directed Medical
Research Program
(301) 682-5507
help@cdmrp.org
Ann Schreiber Mentored Investigator Award
May 6, 2014
"http://www.ocrf.org/wp-content/uploads/2015-AnnSchreiber-LOI-RFP.pdf"
About
This grant provides funding for trainees who are working
under the supervision of a mentor who is a recognized
leader in the field of ovarian cancer research.
Funds/Direct Costs $75,000 total costs over entire
period of support
(212) 268-1002
grants@ocrf.org
North American Neuroendocrine Tumor Society
(NANETS)
Clinical Investigator Scholarship
June 30, 2014
"http://www.nanets.net/research/2014-ncis-scholarshipcriteria"
About
The purpose of the NANETS Clinical Investigator
Scholarship is to encourage clinicians at the end of their
fellowship or beginning of their faculty appointment to
pursue a clinical career focused on neuroendocrine tumors.
Candidates must be in the first 5 years of a faculty
appointment (instructor or above) in an accredited medical
school or other institution in North America (must be on
staff at time of award) and must be a NANETS members.
Program Contact NANETS
(360) 314-4112
Breakthrough Award Levels 1 and 2
May 28, 2014
"http://cdmrp.army.mil/funding/pa/14bcrpbreakthrough12_pa
.pdf"
About
The intent of the Breakthrough Award is to support
promising research that has high potential to lead to or
make breakthroughs in breast cancer. The critical
components of this award mechanism are: --Impact:
Research supported by the Breakthrough Award will have
the potential for a major impact and accelerate progress
toward ending breast cancer. The impact may be near-term
or long-term, but must be significant and move beyond an
incremental advancement. Applications must articulate the
pathway to making a clinical impact for individuals with, or
at risk for, breast cancer, even if clinical impact is not an
immediate outcome. --Research Scope: Research
proposed under this award mechanism may be small- to
large-scale projects, at different stages of idea and
research development. Pre-applications are required and
must be received by May 14, 2014. The sponsor will invite
selected applicants to submit full proposals. If invited, full
proposals must be received by May 28, 2014.
Funds/Direct Costs Level 1: $350,000 direct costs over
3 years; Level 2: $700,000 direct
costs over 3 years
Congressionally Directed Medical
Program Contact
Research Program
(301) 682-5507
help@cdmrp.org
Alex's Lemonade Stand Foundation
Reach Awards
May 30, 2014
"http://www.alexslemonade.org/grants/guidelines"
About
Our Reach Awards are designed to move hypothesisdriven research toward the clinic. The goal of this award is
to support selected "late translational" studies needed to
ultimately initiate a clinical trial. A successful application will
identify an unmet clinical need relevant to the care of
pediatric cancer patients and describe how the proposed
project will allow for the pre-clinical research to be
translated to the clinic while keeping broader clinical testing
and implementation in view.
Program Contact Alex's Lemonade Stand Foundation
(610) 649-3034
Page 9 of 49
Alex's Lemonade Stand Foundation
"A" Award
May 23, 2014
"http://www.alexslemonade.org/grants/guidelines"
About
This grant is designed for young scientists who want to
jump-start their career in pediatric oncology research. The
ideal candidate has an original project that is not currently
being funded. Demonstration of outstanding mentorship
and a future commitment to pediatric cancer investigation
are critical components of a successful application.
initiation of promising new projects or novel ideas by junior
faculty members. Applicants should be within six years of
their first independent research or faculty appointment and
must not currently hold any peer review funding.
Program Contact Nicole Ruiz
(305) 243-3029
nruiz4@med.miami.edu
Program Announcements (PA)
period of support
Program Contact Alex's Lemonade Stand Foundation
Wynnewood
(610) 649-3034
Institute
Understanding and Promoting Health Literacy
(R01)
PAR-13-130
Intramural Funding Opportunities
"http://grants.nih.gov/grants/guide/pa-files/PAR-13-130.html"
Sylvester Comprehensive Cancer Center
Sylvester Acceleration Clinical Trial
Grants 2014
"http://sylvester.org/research/funding-opportunities"
About
The goal of this program is to support the development of
highly innovative, programmatically important investigator
initiated, cooperative group or industry sponsored
therapeutic trials. While investigator initiated trials continue
to be a high priority, and historically have been
underfunded, other types of trials may also test concepts of
high value to the programs of the Cancer Center and to the
community of cancer patients. In order to rapidly accrue to
our cancer clinical trials, funds will be provided to
accelerate trials that are highly competitive. Only Cancer
Center Faculty Members may apply. Trials may focus on
any type of cancer. The trial must have received PRC
approval to be considered.
Funds/Direct Costs $100,000 total costs for 1 year to
cover patient costs and IRB fees
Nicole
Ruiz
Program Contact
(305) 243-3029
nruiz4@med.miami.edu
American Cancer Society (ACS)
Institutional Research Grant - Pilot Projects Grant
May 30, 2014
"http://sylvester.org/research/funding-opportunities"
About
The American Cancer Society Institutional Research Grant
(ACS IRG) - Pilot Projects Grant is providing funds for
meritorious cancer research that cannot be readily
supported through other funding mechanisms. The primary
purpose of the ACS grant is to provide seed funds for the
About
The goal of this program announcement is to encourage
methodological, intervention and dissemination research for
understanding and promoting health literacy. Health literacy
is defined as the degree to which individuals have the
capacity to obtain, process, and understand basic health
information and services needed to make appropriate
health decisions. This FOA utilizes the NIH Research
Project Grant (R01) grant mechanism.
Funds/Direct Costs Application budgets are not limited,
Program Contact Wen-Ying Sylvia Chou
(240) 276-6954
chouws@mail.nih.gov
Institute
Mechanisms, Models, Measurement, &
Management in Pain Research (R01)
PA-13-118
"http://grants1.nih.gov/grants/guide/pa-files/PA-13-118.html"
About
New advances are needed in every area of pain research,
from the micro perspective of molecular sciences to the
macro perspective of behavioral and social sciences.
Although great strides have been made in some areas,
such as the identification of neural pathways of pain, the
experience of pain and the challenge of treatment have
remained uniquely individual and unsolved. Furthermore,
our understanding of how and why individuals transition to
a chronic pain state after an acute injury is limited.
Research to address these issues conducted by
interdisciplinary and multidisciplinary research teams is
strongly encouraged, as is research from
Page 10 of 49
underrepresented, minority, disabled, or women
investigators. This program will use the NIH Research
Project (R01) award mechanism.
Funds/Direct Costs No limit is set on the costs
requested by R01 applicants but
awards will be appropriately tailored
to the proposed work
Program Contact Susan Marden
6701 Democracy Boulevard
Suite 710
Bethesda, MD 20892-4870
(301) 496-9623
mardens@mail.nih.gov
Institute
Obesity Policy Evaluation Research (R01)
PA-13-110
"http://grants.nih.gov/grants/guide/pa-files/PA-13-110.html"
About
This Funding Opportunity Announcement (FOA)
encourages Research Project Grant (R01) applications that
propose to evaluate large scale policy or programs that are
expected to influence obesity related behaviors (e.g.,
dietary intake, physical activity, or sedentary behavior)
and/or weight outcomes in an effort to prevent or reduce
obesity. The National Cancer Institute is particularly
interested in the evaluation of programs or policies that
may affect dietary or physical activity behavior and/or
weight, and studies incorporating economic research. This
FOA utilizes the NIH Research Project Grant (R01) grant
mechanism.
but need to reflect actual needs of
the proposed project
Program Contact Sonia Arteaga
(301) 435-6677
arteagass@nhlbi.nih.gov
Institute
Mechanistic Insights from Birth Cohorts (R01)
PAR-13-109
"http://grants1.nih.gov/grants/guide/pa-files/PAR-13109.html"
About
The sponsors invite applications for novel research on how
prenatal exposures contribute to the etiology of
chronic diseases and health conditions later in life. The
goal of this award is to stimulate research by leveraging
existing birth cohorts to address targeted mechanistic
questions regarding the normal and abnormal
developmental origins of organ systems and/or diseases of
interest to the participating NIH Institutes and Centers. This
FOA will utilize the NIH Research Project (R01) grant
mechanism.
Program Contact Corinne M. Silva
(301) 451-7335
silvacm@mail.nih.gov
Institute
Potential Effects of Metformin on Aging and AgeRelated Conditions: Small-Scale Clin Studies and
Secondary Analysis of Controlled Clin Studies
(R01)
PA-12-271
About
Emerging data from clinical studies of metformin in a variety
of patient populations suggest that it may have other
effects, besides being an antihyperglycemic agent, which
warrant further attention in translational aging research.
The objective of this Funding Opportunity Announcement
(FOA) is to support research projects that include smallscale physiologic studies in humans or secondary analyses
of data and/or stored biospecimens from controlled clinical
intervention studies, to increase our understanding about
the clinical translational potential of metformin to delay
deleterious aging changes or to extend healthy human life
span. This includes identification of specific populations
particularly likely to benefit, and/or to obtain information on
metformin’s human physiologic and cellular effects that
would be useful in identifying novel molecular targets. This
FOA utilizes the NIH (R01) Research Project Grant
mechanism.
Program Contact Chhanda Dutta, PhD
31 Center Drive, MSC 2292
Bethesda, MD 20892
(301) 435-3048
duttac@mail.nih.gov
Examination of Survivorship Care Planning
Efficacy and Impact (R01)
PA-12-275
Page 11 of 49
About
(FOA) is to stimulate research to evaluate the effect of care
planning on cancer survivors' health and psychosocial
outcomes; self-management of late effects and adherence
to cancer screening and health behavior guidelines;
utilization of follow-up care; organizational-level factors
influencing the implementation of care planning; and
associated costs. Specifically, the FOA aims to stimulate
research that will: 1) develop and test metrics for evaluating
the impact of survivorship care planning; 2) evaluate the
impact of survivorship care planning on cancer survivors'
morbidity, self-management and adherence to care
recommendations, utilization of follow-up care, and on
systems outcomes, such as associated costs and impact
on organizations implementing care planning; and 3)
identify models and processes of care that promote
effective survivorship care planning. The ultimate goal of
this FOA is to generate a body of science that will inform
the development and delivery of interventions and best
practices in follow-up care for cancer survivors. This FOA
utilizes the NIH (R01) Research Project Grant mechanism.
Program Contact Stephen Hunt Taplin
(240) 276-6947
carla.parry@nih.gov
Institute
Bioengineering Research Grants (BRG) (R01)
PAR-13-137
About
The purpose of this funding opportunity announcement is to
encourage collaborations between the life and physical
sciences that: 1) apply a multidisciplinary bioengineering
approach to the solution of a biomedical problem; and 2)
integrate, optimize, validate, translate or otherwise
accelerate the adoption of promising tools, methods and
techniques for a specific research or clinical problem in
basic, translational, or clinical science and practice. An
application may propose design-directed, developmental,
discovery-driven, or hypothesis-driven research and is
appropriate for small teams applying an integrative
approach that can increase our understanding of and solve
problems in biological, clinical or translational science. This
mechanism.
Program Contact Houston Baker
(240) 276-5908
bakerhou@mail.nih.gov
Institute
Development of Assays for High-Throughput
Screening for Use in Probe and Pre-therapeutic
Discovery (R01)
PAR-13-364
About
The participating NIH Institutes and Centers invite
Research Project Grant (R01) applications to develop
assays for high throughput screening (HTS) for use in
Probe and Pre-therapeutic Discovery. The NCI is interested
in development of assays to identify or evaluate small
molecules for use in elucidating molecular, cellular, or in
vivo mechanisms or processes of probable or known
importance to cancer biology, and for use in developing
strategies for cancer prevention, diagnosis, treatment or
clinical monitoring of treatment. Assays proposed may be
biochemical, cellular or model organism-based, and may be
useful for discovering small molecule probes, preventive or
therapeutic drug leads, or imaging agent leads. Applicants
may find the NCI Developmental Therapeutics Program
(http://dtp.nci.nih.gov) resources to be helpful.
Collaborations between laboratories with screen
development capabilities and laboratories with small
molecule synthesis capabilities are encouraged. This FOA
utilizes the NIH Research Grants (R01) award mechanism.
Program Contact Suzanne Forry-Schaudies
(240) 276-5922
forryscs@mail.nih.gov
Institute
Accelerating the Pace of Drug Abuse Research
Using Existing Data (R01)
PAR-13-080
About
(FOA) is to invite applications proposing the innovative
analysis of existing social science, behavioral,
administrative, and neuroimaging data to study the etiology
and epidemiology of drug using behaviors (defined as
alcohol, tobacco, prescription and other drug) and related
disorders. Under this FOA, the National Institute on Drug
Abuse (NIDA), National Institute on Alcohol Abuse and
Alcoholism (NIAAA), the National Cancer Institute (NCI),
and the Office of Behavioral and Social Sciences Research
(OBSSR) encourage the analyses of public use and other
extant community-based or clinical datasets to their full
potential in order to increase our knowledge of etiology,
Page 12 of 49
trajectories of drug using behaviors and their
consequences, risk and resilience. This FOA will utilize the
NIH Research Project (R01) grant mechanism.
Program Contact Marsha F. Lopez
6001 Executive Boulevard, Rm. 5144,
MSC 9589
(301) 443-6504
lopezmar@nida.nih.gov
Institute
Academic-Industrial Partnerships for Translation
of in vivo Imaging Systems for Cancer
Investigations (R01)
PAR-13-169
About
National Cancer Institute (NCI) invites applications from
research partnerships formed by academic and industrial
investigators to accelerate the translation of either
preclinical or clinical in vivo imaging systems and/or
methods that are designed to solve a targeted cancer
problem. The proposed imaging system/methods may
include single or multi modality in vivo imaging and
spectroscopy systems, image-guided and drug delivery
systems, image analysis, and related research resources.
This FOA utilizes the NIH Research Project Grant (R01)
grant mechanism.
Funds/Direct Costs The amount of funds requested and
their distribution between years
should be tailored to the needs of
the project, usually less than
$500,000 in total direct costs in any
one year of the project
(240) 276-5908
Institute
Innovative Research Methods: Prevention and
Management of Symptoms in Chronic Illness (R01)
PA-13-165
About
This funding opportunity seeks to update the randomized
control trial (RCT) design using novel research methods
that are practical, innovative, and hold promise for
producing more effective outcomes. Novel clinical research
designs, applied to symptom management trials, may
identify those treatment strategies that best alter the course
of symptom burden in chronic illness by addressing the
issues of varied treatment responses across patients,
subject retention, and adherence to treatment regimens.
This FOA will utilize the NIH Research Project Grant (R01)
award mechanism.
Budgetary Notes R01 Applications with budgets of
$350,000 or less in direct costs per year
are encouraged
Program Contact Emily Tran
(240) 276-6324
trane@mail.nih.gov
Institute
Chronic Inflammation and Age-related Disease
(R01)
PAR-13-233
About
Applications are invited to address both the origins and the
effects of low level chronic inflammation in the onset and
progression of age-related diseases and conditions.
Chronic inflammation, as defined by elevated levels of both
local and systemic cytokines and other pro-inflammatory
factors, is a hallmark of aging in virtually all higher animals
including humans and is recognized as a major risk factor
for developing age-associated diseases. A clear
understanding of how chronic inflammation compromises
the integrity of cells or tissues leading to disease
progression is lacking. Thus, there is a critical need to
establish the knowledge base that will allow a better
understanding of the complex interplay between
inflammation and age-related diseases. Applications
submitted to this FOA should aim to clarify the molecular
and cellular basis for the increase in circulating
inflammatory factors with aging, and/or shed light on the
cause-effect relationship between inflammation and
disease, using pre-clinical (animal or cellular based)
models. This FOA utilizes the NIH Research Grants (R01)
grant mechanism.
Page 13 of 49
Program Contact Ron Johnson
(240) 276-6228
rjohnso2@mail.nih.gov
Institute
Research to Characterize and Reduce Stigma to
Improve Health (R01)
PA-13-248
About
The National Cancer Institute encourages research
focused on associations between experienced stigma and
biological cancer outcomes; associations between stigma
and stress, negative affectivity, and/ or social isolation;
ways in which health disparities are exacerbated or
perpetuated by stigma. It also encourages research on the
health and economic impact of other forms of
discrimination, including racial or ethnic discrimination or
discrimination arising from lower socioeconomic status, as
well as stigma associated with cancer. Another area of
interest concerns the influence of stigma on process of care
behaviors and medical decisions (e.g., willingness to seek
preventive services), particularly among cultures with
cancer-related stigma convictions (e.g., Vietnamese and
other Asian American populations). Other areas of research
include but are not limited to factors that contribute to the
internalization of a stigmatized identity; studies that address
the role of compounding or interactive stigmatized
identities; and, factors that may attenuate or buffer against
stigma or stigma-related consequences (e.g., positive
affectivity, social support). Of particular interest are
intervention or health communication studies aimed at
targeting cancer-related stigma and methodological studies
aimed at improving detection of cancer-related stigmas.
award mechanism.
Program Contact Luis A. Salicrup
(240) 276-5810
salicrul@mail.nih.gov
About
(FOA) is to invite qualified basic science and clinical
investigators to submit applications for research projects
designed to advance the understanding of pathogenic
mechanisms underlying systemic amyloidosis, to develop
improved techniques (in particular those that are noninvasive) for the clinical detection and diagnosis of systemic
amyloid diseases, to develop novel cellular and in vivo
models with which to identify candidate therapeutic agents,
and to evaluate the clinical efficacy of novel therapies
designed to prevent, arrest, and (when possible) reverse
the morbid and lethal progression of these diseases. The
National Cancer Institute (NCI) is interested in sponsoring
research relevant to the diagnosis and treatment of Amyloid
Light-chain (AL) Amyloidosis, particularly that relating to the
characterization, detection, and control or elimination of
clonal plasma cell disorders that underlie this form of
amyloidosis. This FOA utilizes the NIH Research Project
Grant (R01) award mechanism.
Program Contact Rebekah Rasooly
(301) 594-6007
rasoolyr@mail.nih.gov
Institute
Research on the Health of LGBTI Populations (R01)
PA-12-111
About
The National Institutes of Health (NIH) is committed to
supporting research that will increase scientific
understanding of the health status of various population
groups and improve the effectiveness of health
interventions and services for individuals within those
groups. High priority is placed on research on populations
that appear to have distinctive health risk profiles but have
received insufficient attention from investigators. This
Funding Opportunity Announcement (FOA) highlights a
particular community: lesbian, gay, bisexual, transgender,
intersex, and related populations (designated here as
LGBTI populations). Basic, social, behavioral, clinical, and
services research relevant to the missions of the
sponsoring Institutes and Centers may be proposed. This
mechanism.
Institute
Systemic Amyloidosis: Basic, Translational, and
Clinical Research (R01)
PA-13-286
Page 14 of 49
Program Contact Rebecca Liddell Huppi, PhD
31 Center Drive, Suite 3A33
(301) 496-4995
liddellr@exchange.nih.gov
Institute
Behavioral and Social Science Research on
Understanding and Reducing Health Disparities
(R01)
PA-13-292
About
The purpose of this FOA is to encourage behavioral and
social science research on the causes and solutions to
health and disabilities disparities in the U. S. population.
Health disparities between, on the one hand, racial/ethnic
populations, lower socioeconomic classes, and rural
residents and, on the other hand, the overall U.S.
population are major public health concerns. Emphasis is
placed on research in and among three broad areas of
action: 1) public policy, 2) health care, and 3)
disease/disability prevention. Particular attention is given to
reducing “health gaps” among groups. Applications that
utilize an interdisciplinary approach, investigate multiple
levels of analysis, incorporate a life-course perspective,
and/or employ innovative methods such as systems
science or community-based participatory research are
particularly encouraged. This FOA utilizes the NIH
Research Grants (R01) award mechanism.
Funds/Direct Costs Application budgets are not limited
Program Contact Shobha Srinivasan
(240) 276-6938
ss688k@nih.gov
Institute
Translational Research at the Aging/Cancer
Interface (TRACI) (R01)
PA-12-136
About
encourages translational research proposals in the
overlapping areas of human aging and cancer, linking basic
and clinical research relevant to the care of older cancer
patients through both bench-to-bedside and bedside-tobench approaches. Ultimately, information from the
research supported by this initiative should improve the
health and well-being of elderly patients at risk for, or
diagnosed with, cancer and decrease the functional
impairment and morbidity associated with cancer in this
population. This FOA utilizes the Research Project Grant
(R01) grant mechanism.
Program Contact Kevin Howcroft
(301) 496-7815
howcrofk@mail.nih.gov
Institute
Modeling Social Behavior (R01)
PAR-13-374
About
encourages applications for developing and testing
innovative theories and computational, mathematical, or
engineering approaches to deepen our understanding of
complex social behavior. This research will examine
phenomena at multiple scales to address the emergence of
collective behaviors that arise from individual elements or
parts of a system working together. Emergence can also
describe the functioning of a system within the context of its
environment. Often properties we associate with a system
itself are in actuality properties of the relationships and
interactions between a system and its environment. This
FOA will support research that explores the often complex
and dynamic relationships among the parts of a system and
between the system and its environment in order to
understand the system as a whole. To accomplish the
goals of this initiative, we encourage applications that build
transdisciplinary teams of scientists spanning a broad
range of expertise. Minimally this team should include
investigators with expertise in the behavioral or social
sciences as well as in computational and systems modeling
(computer science, mathematics, engineering, or other
systems sciences). Applications should demonstrate bridgebuilding between disciplines, scales and levels. This FOA
utilizes the NIH Research Grants (R01) award mechanism.
Program Contact William Riley
(240) 276-6973
wiriley@mail.nih.gov
Page 15 of 49
Institute
Quantitative Imaging for Evaluation of Response
to Cancer Therapies (U01)
PAR-14-116
About
The National Cancer Institute (NCI) invites applications
which are expected to enhance the value of quantitative
imaging (QI) in clinical trials for prediction and/or
measurement of response to cancer therapies. One
avenue for this enhancement is to emphasize the
development, optimization and validation of state-of-the-art
QI methods and software tools for potential implementation
in single site phase 1 or 2 clinical trials. The second avenue
to enhance QI methods is to address the challenges of
integrating existing and or new QI methods as required for
multicenter phase 3 clinical trials. This may involve
evaluation of a range of multimodal imaging approaches,
harmonization of image data collection, analysis, display
and clinical workflow methods across imaging platforms, or
testing their performance across different cancer sites.
Because this validation process is complex, a single
research program cannot be expected to complete every
detail from initial tool development to final integration into
clinical trials. Therefore, it is anticipated that these research
goals will require multidisciplinary efforts. Although the
involvement of industrial partners in the development of the
QI methods is not required, it is strongly encouraged.
Awardees will also join the Quantitative Imaging Network
(QIN) to share ideas and approaches in order to validate
and standardize imaging data and related imaging
metadata for quantitative measurements of prediction
and/or response to cancer therapies. This FOA will utilize
the NIH (U01) cooperative agreement award mechanism.
Period of Support up to 5 years
Program Contact Robert Nordstrom
(240) 276-5934
nordstrr@mail.nih.gov
Physical Activity and Weight Control Interventions
Among Cancer Survivors: Effects on Biomarkers
of Prognosis and Survival (R01)
PAR-12-228
About
National Cancer Institute (NCI) invites applications for
transdisciplinary and translational research that will identify
specific biological or biobehavioral pathways through which
physical activity and/or weight control (either weight loss or
avoidance of weight gain) may affect cancer prognosis and
survival. Research applications must test the effects of
physical activity or weight control or both interventions on
biomarkers of cancer prognosis among cancer survivors
identified by previous animal or observational research,
which may include but are not limited to interventioninduced changes in sex hormones, insulin or insulin-like
growth factors or their binding proteins, insulin resistance,
glucose metabolism, leptin and other adipokines,
immunologic or inflammatory factors, oxidative stress and
DNA damage or repair capacity, angiogenesis, or
prostaglandins. This research will require transdisciplinary
approaches that bring together behavioral intervention
expertise, cancer biology, and other basic and clinical
science disciplines relevant to the pathways being studied.
This FOA will use the NIH Research Project (R01) award
mechanism.
requested by R01 applicants
however, costs should be
appropriately tailored to the
proposed work
Program Contact Catherine M. Alfano
(240) 276-6736
alfanoc@mail.nih.gov
Institute
Ethical Legal and Social Implications (ELSI) of
Genomic Research Regular Research Program
(R01)
PA-11-250
About
encourages applications that propose to study the ethical,
legal and social implications (ELSI) of human genome
research. The NCI is interested in empirical research that
focuses on the ethical, legal and social issues related to
heritable cancer syndromes. Study of the psycho-social
and behavioral impact on affected individuals, their families
and populations and research that takes into consideration
the perspectives of diverse racial, ethnic and
socioeconomic backgrounds, as well as children, older
adults and people with disabilities is highly desirable. The
ultimate goal of this research will be to improve outcomes
related to the diagnosis of heritable cancer syndromes.
This FOA will utilize the NIH Research Project Grant (R01)
award mechanism.
Program Contact Charlisse Caga-Anan
(240) 276-6738
charlisse.caga-anan@nih.gov
Page 16 of 49
Institute
Research on Malignancies in the Context of
HIV/AIDS (R01)
PA-13-377
About
National Cancer Institute (NCI) and National Institute of
Dental and Craniofacial Research (NIDCR) invite
applications from institutions/organizations that propose to
continue advancing our understanding of the risks,
development, progression, diagnosis, and treatment of
malignancies observed in individuals with an underlying
Human Immunodeficiency (HIV) infection or Acquired
Immune Deficiency Syndrome (AIDS). The NCI and NIDCR
encourage research in areas such as the study of the
etiologic factors, cofactors, immunopathogenesis,
diagnosis, and consequences of both non-AIDS defining
and AIDS-defining malignancies in diverse populations.
This FOA encourages research efforts that will (i) provide
information on the clinical outcomes of such cancers in the
HIV-infected population and (ii) identify specific
contributions resulting from HIV infection and its potential
interaction with other pathogens for the development and
pathogenesis of these cancers. Ultimately, such efforts
could inform screening approaches and therapies targeted
to the HIV-infected population. This program utilizes the
NIH Research Project (R01) award mechanism.
but, costs should be appropriately
tailored to the proposed work
Program Contact Geraldina Dominguez
(301) 496-3204
domingug@mail.nih.gov
Institute
Research on Malignancies in the Context of
HIV/AIDS (R21)
PA-13-378
About
This funding opportunity announcement (FOA) encourages
Research Project Grant (R21) applications from
institutions/organizations that propose to continue
advancing our understanding of the risks, development,
progression, diagnosis, and treatment of malignancies
observed in individuals with an underlying Human
Immunodeficiency (HIV) infection or Acquired Immune
Deficiency Syndrome (AIDS). The National Cancer Institute
encourages research in areas such as the study of the
etiologic factors, cofactors, immunopathogenesis,
diagnosis, and consequences of both non-AIDS defining
and AIDS-defining malignancies in diverse populations.
This FOA encourages research efforts that will (i) provide
information on the clinical outcomes of such cancers in the
HIV-infected population and (ii) identify specific
contributions resulting from HIV infection and its potential
interaction with other pathogens for the development and
pathogenesis of these cancers. Ultimately, such efforts
could inform screening approaches and therapies targeted
to the HIV-infected population. This FOA utilizes the NIH
Exploratory/Developmental Research Grant (R21) award
mechanism.
period of support
Budgetary Notes No more than $200,000 may be
requested in any single year
Program Contact Geraldina Dominguez
(301) 496-3204
domingug@mail.nih.gov
Institute
Interventions for Health Promotion and Disease
Prevention in Native American Populations (R01)
PAR-11-346
About
(FOA) is to develop, adapt, and test the effectiveness of
health promotion and disease prevention interventions in
Native American (NA) populations. The National Cancer
Institute (NCI) is interested in applications that focus on
both individual and community interventions relating to
primary and secondary (screening) cancer prevention. It is
important that researchers consider the context in which
people live and develop interventions that can improve
overall health and result in better health outcomes as they
relate to cancer. The intervention program should be
designed so that it could be sustained within the entire
community within existing resources, and, if successful,
disseminated in other Native American communities. The
long-term goal of this FOA is to reduce mortality and
morbidity in NA communities. For the purposes of this FOA
Native Americans include the following populations: Alaska
Native, American Indian, and Native Hawaiian. This FOA
will utilize the NIH (R01) Research Project Grant award
mechanism.
Program Contact Shobha Srinivasan
(240) 276-6938
ss688k@nih.gov
Page 17 of 49
Institute
Specialized Programs of Research Excellence
(SPOREs) in Human Cancer for Year 2014 (P50)
PAR-14-031
within 5-10 years. This FOA utilizes the NIH Research
Project Grant (R01) funding mechanism.
(240) 276-5908
About
The program will fund Specialized Programs of Research
Excellence (SPORE) grants to support state-of-the-art
investigator-initiated translational research that will
contribute to improved prevention, early detection,
diagnosis, and treatment of an organ-specific cancer (or a
related group of cancers). SPOREs are expected not only
to conduct a wide spectrum of research activities, but also
to contribute significantly to the development of specialized
shared resource core facilities (cores), improved research
model systems, and collaborative research projects with
other institutions. The research supported through this
program must be translational in nature and must always
be focused upon knowledge of human biology stemming
from research using cellular, molecular, structural,
biochemical, and/or genetic experimental approaches with
the goal of a translational human endpoint within the 5 year
term of the grant. In addition, SPOREs must include both a
Developmental Research Program for pilot studies and a
Career Development Program to foster careers in organbased translational science. This Funding Opportunity
Announcement (FOA) utilizes the NIH Specialized Center
Grant (P50) award mechanism.
About
investigator-initiated program project (P01) grants.
Proposed program projects may address any of the broad
areas of cancer research, including (but not limited to)
cancer biology, cancer treatment, cancer diagnosis, cancer
prevention, and cancer control. Basic, translational, clinical,
and/or population-based studies in all of these research
areas are appropriate. Each Program Project application
must consist of at least three component projects. The
component projects must share a common central theme,
focus, and/or overall objective. This FOA will utilize the NIH
Program Project (P01) grant mechanism.
Funds/Direct Costs Up to $2.5M total costs per year
Program Contact Toby T. Hecht, PhD
(301) 496-8528
hechtt@mail.nih.gov
Program Contact Referral Officer
(240) 276-6390
ncirefof@dea.nci.nih.gov
Institute
Bioengineering Research Partnerships (BRP) R01
PAR-14-092
Institute
Behavioral Interventions to Address Multiple
Chronic Health Conditions in Primary Care (R01)
PA-14-114
About
encourages bioengineering applications that will accelerate
the development and adoption of promising tools and
technologies that can address important biomedical
research problems. The objectives are to establish these
tools and technologies as robust, well-characterized
solutions that fulfill an unmet need and are capable of
enhancing our understanding of life science processes or
the practice of medicine. Awards will focus on supporting
multidisciplinary teams that apply an integrative,
quantitative bioengineering approach to developing these
technologies and engage biomedical researchers or
clinicians throughout the project. The goal of the program is
to support projects that can realize meaningful solutions
National Cancer Institute Program Project (P01)
Applications
PAR-13-321
About
This funding opportunity announcement (FOA) seeks
Research Project Grant (R01) applications that propose to
use a common conceptual model to develop behavioral
interventions to modify health behaviors and improve health
outcomes in patients with comorbid chronic diseases and
health conditions. Specifically, this FOA will support
research in primary care that uses a multi-disease care
management approach to behavioral interventions with
high potential impact to improve patient-level health
outcomes for individuals with three or more chronic health
conditions. The proposed approach must modify behaviors
using a common approach rather than administering a
distinct intervention for each targeted behavior and/or
Page 18 of 49
condition. Diseases and health conditions can include, but
are not limited to: mental health disorders (e.g.,
depression), diabetes, smoking, obesity, chronic pain,
alcohol and substance abuse and dependence, chronic
obstructive pulmonary disorder, cancer and hypertension.
award mechanism.
Program Contact Veronica Chollette
(301) 435-2837
cholletv@exchange.nih.gov
NEW
Early Phase Clinical Trials in Imaging and ImageGuided Interventions (R01)
PAR-14-166
About
The National Cancer Institute (NCI) invites applications for
clinical trials conducting preliminary evaluation of the safety
and efficacy of imaging agents, as well as an assessment
of imaging systems, image processing, image-guided
therapy, contrast kinetic modeling, 3-D reconstruction and
other quantitative tools. As many such preliminary
evaluations are early in development, this FOA will provide
investigators with support for pilot (Phase I and II) cancer
imaging clinical trials, including patient monitoring and
laboratory studies. This FOA supports novel uses of
known/standard clinical imaging agents and methods as
well as the evaluation of new agents, systems, or methods.
The imaging and image guided intervention (IGI)
investigations, if proven successful in these early clinical
trials, can then be validated in larger studies through
competitive R01 mechanisms, or through clinical trials in
the Specialized Programs of Research Excellence
(SPOREs), Cancer Centers and/or the NCI's National
Clinical Trials Network. This FOA utilizes the NIH
Research Project (R01) award mechanism.
Funds/Direct Costs $5000,000 direct costs over entire
period of support
Budgetary Notes No more than $250,000 in direct costs
may be requested in any single year
Program Contact Lori A. Henderson
(240) 276-5930
hendersonlori@mail.gov
Institute
Improving Diet and Physical Activity Assessment
(R01)
PAR-12-198
About
encourages innovative research to enhance the quality of
measurements of dietary intake and physical activity.
Applications submitted under this FOA may include
development of: novel assessment approaches; better
methods to evaluate instruments; assessment tools for
culturally diverse populations or various age groups,
including older adults; improved technology or applications
of existing technology; statistical methods to assess or
correct for measurement errors or biases, methods to
investigate the multidimensionality of diet and physical
activity behavior through pattern analysis; or integrated
measurement of diet and physical activity along with the
environmental context of such behaviors. This FOA utilizes
the Research Project Grant (R01) grant mechanism.
Program Contact Amy Subar, PhD
6130 Executive Boulevard, Room
4005
(301) 594-0831
subara@mail.nih.gov
Institute
Mechanisms of Alcohol-Associated Cancers (R01)
PA-12-146
About
This Funding Opportunity Announcement (FOA) invites
applications from researchers with broad ranges of
expertise to study the mechanisms by which alcohol
increases cancer risk. Target sites for alcohol-related
carcinogenesis include the oral cavity, pharynx, esophagus,
larynx, breast, liver, and colon. A better understanding of
the molecular basis by which alcohol increases cancer risk
could lead to improved therapeutic approaches and
preventative strategies and would provide guidance on safe
levels of alcohol consumption. The goal of this program
announcement is to stimulate a broad range of research
into the mechanisms by which alcohol contributes to
carcinogenesis. This FOA utilizes the NIH Research Project
Grant (R01) award mechanism.
Page 19 of 49
Program Contact Sharon Ross, PhD
3157
Rockville, MD 20852
(301) 594-7547
rosssha@mail.nih.gov
About
encourages applications to validate the clinical utility of new
molecular diagnostics for determining prognosis or
predicting response to therapy or toxicity for cancer. This
program will support research projects to improve clinical
decision-making in the care of cancer patients and as such
will support studies that use tumor specimens linked to
specific treatment and clinical outcome information. This
FOA is not appropriate for molecular diagnostics discovery
projects. This FOA utilizes the NIH Research Project Grant
(R01) mechanism.
Institute
Biomechanisms of Peripheral Nerve Damage by
Anti-Cancer Therapy (R01)
PA-12-082
Program Contact Magdalena Thurin, PhD
(301) 496-1591
thurinm@mail.nih.gov
About
(FOA) is to encourage basic biologic research on damage
to the peripheral nervous system instigated by
pharmacologic cancer treatments, known as chemotherapyinduced peripheral neuropathy (CIPN). This FOA intends to
stimulate neuroscience researchers to apply their expertise
from studying neuropathies focused on diabetic and
inherited diseases to the injuries incurred by cancer
treatments. More data is necessary to understand the
mechanisms of neuronal damage and to identify the targets
instrumental to CIPN initiation and maintenance. Preclinical
research that focuses not only on peripheral neuropathic
pain but also on neurosensory symptoms such as
paresthesias and peripheral anesthesias is invited. The
ultimate goal of this FOA is to lead to a molecular
understanding of CIPN that allows for the rational
development of interventions that will treat or prevent CIPN.
grant mechanism.
About
encourages research projects for the development and
validation of biomarkers for: a) early detection, prediction of
progression, and recurrence of hematopoietic
malignancies, especially in high-risk individuals; and, b) for
risk assessment of primary and secondary hematopoietic
malignancies. This FOA also encourages the development
and improvement of specific technologies and methods for
quantitative detection of novel biomarkers associated with
hematopoietic malignancies. This FOA utilizes the NIH
Research Project (R01) award mechanism.
Program Contact Joanna M. Brell, MD
2014
Bethesda
(301) 496-8541
brelljm@mail.nih.gov
Program Contact Lynn Sorbara
3137
(301) 435-0584
lynns@mail.nih.gov
Validation of Molecular Diagnostics to Predict
Patient Outcomes Using Specimens from MultiSite Cancer Trials (R01)
PA-12-013
Innovative Molecular Analysis Technology
Development for Cancer Research and Clinical
Care (R43/R44)
PAR-13-327
Biomarkers for Early Detection of Hematopoietic
Malignancies (R01)
PA-12-221
Page 20 of 49
About
Small Business Innovation Research (SBIR) from small
business concerns (SBCs) proposing research for
commercial development of novel cancer-relevant
technologies. The proposed research projects are expected
to focus on the development of highly-innovative
technologies that improve molecular and/or cellular
analysis of cancer with a significant likelihood for either
overcoming persistent challenges or obstacles or opening
entirely new fields for cancer research or clinical care.
Applications should specify milestones relevant to both
the development and commercialization of these
technologies. This FOA complements the goals of the NCI's
Innovative Molecular Analysis Technologies (IMAT)
program by facilitating the path towards technology
commercialization. Prior participation in the IMAT Program
is not required for eligibility for this FOA. Applications are
expected to indicate the significant attributes and
advantages of the proposed technology over currently
available technologies and conventional approaches. This
FOA will utilize the SBIR (R43/R44) grant mechanisms for
Phase I, Phase II, and Fast-Track applications.
Period of Support 6 months for Phase I and 2 years for
Phase II
Funds/Direct Costs Up to $225,000 for Phase I and
$1,500,000 for Phase II total costs
for entire period of support
Program Contact Amir Rahbar
(240) 276-5230
rahbaram@mail.nih.gov
Identifying Non-coding RNA Targets for Early
Detection of Cancer (R01)
PA-12-213
About
encourages research projects on non-coding RNAs
(ncRNAs) and their targets in preneoplastic lesions and
early stage cancers. This FOA also encourages research
projects to assess the usefulness of stable microRNAs
(miRNAs) and ncRNAs to predict progression to cancer
and as biomarkers for early cancer detection and
screening. Building on both basic and biomarker research
on microRNAs (miRNA), this FOA will further promote
research on all classes of ncRNAs and support the
translation of stable miRNAs into cancer screening or
diagnostic tests. This FOA utilizes the NIH Research
Project (R01) grant mechanism.
the propsed project
Program Contact Wendy Wang
3138
(301) 594-7607
wangw@mail.nih.gov
Institute
Spatial Uncertainty: Data, Modeling, and
Communication (R01)
PA-11-238
About
(FOA) is to support innovative research that identifies
sources of spatial uncertainty (i.e., inaccuracy or instability
of spatial or geographic information) in public health data,
incorporates the inaccuracy or instability into statistical
methods, and develops novel tools to visualize the nature
and consequences of spatial uncertainty. The National
Cancer Institute (NCI) is interested in general methodology
of spatial statistical models and visualization tools that are
applicable to disease control and prevention especially as
related to cancer and cancer patients. This FOA utilizes the
NIH Research Project Grant (R01) grant mechanism.
Program Contact Li Zhu, PhD
(301) 594-6546
li.zhu@nih.gov
Institute
Systems Science and Health in the Behavioral and
Social Sciences (R01)
PAR-11-314
About
encourages applications that propose to develop basic and
applied projects utilizing systems science methodologies
relevant to human behavioral and social sciences and
health. This FOA is intended to encourage a broader scope
of topics to be addressed with systems science
methodologies, beyond those encouraged by existing open
FOAs. Research projects applicable to this FOA are those
that are either applied or basic in nature (including
methodological development), have a human behavioral
Page 21 of 49
and/or social science focus, and feature systems science
methodologies. NCI is interested in research projects that
address the cause, diagnosis, prevention, and treatment of
cancer, rehabilitation from cancer, and the continuing care
of cancer patients and the families of cancer patients. This
FOA utilizes the NIH Research Project Grant (R01) award
mechanism.
Program Contact Kara L. Hall, PhD
(240) 276-6831
hallka@mail.nih.gov
Institute
Solicitation of Assays for High Throughput
Screening (HTS) to Discover Chemical Probes
(R01)
PAR-12-058
About
encourages investigators to form collaborations with an
established academic, nonprofit, or commercial high
throughput screening (HTS) facility that has the requisite
expertise and experience to implement HTS-ready assays
for the discovery and development of small molecule
chemical probes. Through this FOA, the NCI is interested in
high throughput screens intended to identify small
clinical monitoring of treatment. Screens may be
biochemical, cellular or model organism-based. High
throughput screens for targets that address unmet needs in
cancer prevention, treatment or diagnosis are encouraged.
award mechanism.
the propsed project
Program Contact Suzanne Forry-Schaudies, PhD
(301) 435-9147
Institute
Solicitation of Validated Hits for the Discovery of
in vivo Chemical Probes (R01)
PAR-12-060
About
This Funding Opportunity Announcement (FOA) intends to
support investigators who have interest and capability to
join efforts for the discovery of in vivo chemical probes. It is
expected that applicants will have in hand the starting
compounds (“validated hits”) for chemical optimization and
bioassays for testing new analog compounds. Through this
FOA, the NCI is particularly interested in validated hits for
targets that address unmet needs in the prevention,
treatment, or diagnosis of cancer. Strategies that include
testing of in vivo chemical probe activity in primary human
tumor cells are encouraged. This FOA utilizes the NIH
Research Project Grant (R01) award mechanism.
(301) 435-9147
Institute
Dissemination and Implementation Research in
Health (R01)
PAR-13-055
About
This FOA encourages investigators to submit research
grant applications that will identify, develop, and refine
effective and efficient methods, structures, and strategies
that test models to disseminate and implement researchtested health behavior change interventions and evidencebased prevention, early detection, diagnostic, treatment,
and quality of life improvement services into public health
and clinical practice settings. This FOA will use the NIH
Research Project Grant (R01) award mechanism.
Program Contact David A. Chambers
(301) 443-3747
dchamber@mail.nih.gov
Page 22 of 49
Institute
Advancing the Science of Geriatric Palliative Care
(R21)
PA-13-355
About
encourages research grant applications focused on
palliative care in geriatric populations. This FOA
emphasizes studies in a variety of settings including
ambulatory care, hospitals (and specific sites within
hospitals including specialty wards, intensive care units and
emergency departments), assisted living facilities, and
short- and long-term care facilities; however, hospice and
end-of-life settings are not included within the scope of this
FOA, as they are the subject of other NIH programs.
Rather, this FOA highlights research on palliative care in
settings and at time points earlier in geriatric patients'
disease or disability trajectories. Types of studies may
include observational, quasi-experimental, or interventional
studies using primary data collection and/or secondary
analyses. Leveraging on-going cohorts, intervention
studies, networks, data and specimen repositories, and
other existing resources and infrastructure are encouraged.
NCI’s focus includes studies that identify factors that
contribute to tolerance of and adherence to cancer
therapies and improved enrollment and retention in clinical
trials. This FOA utilizes the NIH (R21) Exploratory/
Developmental Research Grant award mechanism.
Funds/Direct Costs $275,000 direct costs for entire
period of support
Program Contact Basil Eldadah
(301) 496-6761
basil.eldadah@nih.gov
Institute
Biomechanisms of Peripheral Nerve Damage by
Anti-Cancer Therapy (R21)
PA-12-083
About
(FOA) is to encourage basic biologic research on damage
to the peripheral nervous system instigated by
pharmacologic cancer treatments, known as chemotherapyinduced peripheral neuropathy (CIPN). This FOA intends to
stimulate neuroscience researchers to apply their expertise
from studying neuropathies focused on diabetic and
inherited diseases to the injuries incurred by cancer
treatments. More data is necessary to understand the
mechanisms of neuronal damage and to identify the targets
instrumental to CIPN initiation and maintenance. Preclinical
research that focuses not only on peripheral neuropathic
pain but also on neurosensory symptoms such as
paresthesias and peripheral anesthesias is invited. The
ultimate goal of this FOA is to lead to a molecular
understanding of CIPN that allows for the rational
development of interventions that will treat or prevent CIPN.
This FOA utilizes the NIH Exploratory/Developmental (R21)
Research Grant Award mechanism.
period of support, up to $200,000
direct costs allowed in any single
year
Program Contact Joanna M. Brell, MD
(301) 496-8541
brelljm@mail.nih.gov
Institute
PA-12-112
About
FOA utilizes the NIH Small Grant Program (R03) award
mechanism.
Program Contact Rebecca Liddell Huppi PhD
(301) 496-4995
Institute
PA-12-113
Page 23 of 49
About
FOA utilizes the NIH Exploratory/Developmental Research
Grant Award (R21) mechanism.
year
Program Contact Rebecca Liddell Huppi
(301) 496-4995
PAR-12-229
About
encourages transdisciplinary and translational research
that will identify specific biological or biobehavioral
pathways through which physical activity and/or weight
control (either weight loss or avoidance of weight gain) may
affect cancer prognosis and survival. Research applications
must test the effects of physical activity or weight control or
both interventions on biomarkers of cancer prognosis
among cancer survivors identified by previous animal or
observational research, which may include but are not
limited to intervention-induced changes in sex hormones,
insulin or insulin-like growth factors or their binding
proteins, insulin resistance, glucose metabolism, leptin and
other adipokines, immunologic or inflammatory factors,
oxidative stress and DNA damage or repair capacity,
angiogenesis, or prostaglandins. This research will require
transdisciplinary approaches that bring together behavioral
intervention expertise, cancer biology, and other basic and
clinical science disciplines relevant to the pathways being
studied. This FOA utilizes the NIH Exploratory/
Developmental Research Grant Award (R21) mechanism.
Budgetary Notes $275,000 direct costs over entire period
of support, with no more than $200,000
Program Contact Catherine M. Alfano, PhD
(240) 276-6736
Examination of Survivorship Care Planning
Efficacy and Impact (R21)
PA-12-274
About
(FOA) is to stimulate research to evaluate the effect of care
planning on cancer survivors' health and psychosocial
outcomes; self-management of late effects and adherence
to cancer screening and health behavior guidelines;
utilization of follow-up care; organizational-level factors
influencing the implementation of care planning; and
associated costs. Specifically, the FOA aims to stimulate
research that will: 1) develop and test metrics for evaluating
the impact of survivorship care planning; 2) evaluate the
impact of survivorship care planning on cancer survivors'
morbidity, self-management and adherence to care
recommendations, utilization of follow-up care, and on
systems outcomes, such as associated costs and impact
on organizations implementing care planning; and 3)
identify models and processes of care that promote
effective survivorship care planning. The ultimate goal of
this FOA is to generate a body of science that will inform
the development and delivery of interventions and best
practices in follow-up care for cancer survivors. This FOA
utilizes the NIH Exploratory/Developmental Research Grant
(R21) Award mechanism.
may be requested in any single year
Program Contact Stephen Hunt Taplin
(240) 276-6947
taplins@mail.nih.gov
Institute
Exploratory/Developmental Bioengineering
Research Grants (EBRG) (R21)
PA-12-284
Page 24 of 49
About
(FOA) is to encourage Exploratory/Developmental
Bioengineering Research Grants (EBRG) applications
which establish the feasibility of technologies, techniques or
methods that: 1) explore a unique multidisciplinary
approach to a biomedical challenge; 2) are high-risk but
have a considerable pay-off; and 3) develop data which can
lead to significant future research. An EBRG application
may propose hypothesis-driven, discovery-driven,
developmental, or design-directed research and is
appropriate for evaluating unproven approaches for which
there is minimal or no preliminary data. This FOA utilizes
the NIH Exploratory/ Developmental Research Grant Award
(R21) mechanism.
Program Contact NIH grant resources
(301) 435-0714
GrantsInfo@nih.gov
period of support, with up to
$200,000 in direct costs allowed in
any single year
Program Contact Houston Baker, PhD
(240) 276-5908
About
health decisions. This FOA utilizes the NIH Research Grant
(R03) mechanism.
NEW
Program Contact Wen-ying Sylvia Chou
(240) 276-6954
chouws@mail.nih.gov
Institute
Early Stage Development of Technologies in
Biomedical Computing, Informatics, and Big Data
Science (R01)
PA-14-155
About
The NIH is interested in promoting a broad base of
research and development of technologies in biomedical
computing, informatics, and Big Data Science that will
support rapid progress in areas of scientific opportunity in
biomedical research. It is expected that this research and
development is conducted in the context of important
biomedical and behavioral research problems. As such,
applications are intended to develop enabling technologies
that could apply to the interests of most NIH Institutes and
Centers and range from basic biomedicine and including
research to all relevant organ systems and diseases. Major
themes of research include collaborative environments;
data integration; analysis and modeling methodologies; and
novel computer science and statistical approaches. New
opportunities are also emerging as large and complex data
sets are becoming increasingly available to the research
community. This initiative aims to address biomedical
research areas in biomedical computing, informatics, and
Big Data science through the early stage development of
new software, tools and related resources, as well as the
fundamental research (e.g., methodologies and
approaches) leading up to that development. This FOA
utilizes the NIH (R01) Research Project award mechanism.
Institute
(R03)
PAR-13-131
Institute
(R01)
PA-13-354
About
palliative care in geriatric populations. This FOA
emphasizes studies in a variety of settings including
ambulatory care, hospitals (and specific sites within
hospitals including specialty wards, intensive care units and
emergency departments), assisted living facilities, and
short- and long-term care facilities; however, hospice and
end-of-life settings are not included within the scope of this
FOA, as they are the subject of other NIH programs.
Rather, this FOA highlights research on palliative care in
settings and at time points earlier in geriatric patients'
disease or disability trajectories. Types of studies may
include observational, quasi-experimental, or interventional
studies using primary data collection and/or secondary
analyses. Leveraging on-going cohorts, intervention
studies, networks, data and specimen repositories, and
other existing resources and infrastructure are encouraged.
NCI’s focus includes studies that identify factors that
contribute to tolerance of and adherence to cancer
therapies and improved enrollment and retention in clinical
Page 25 of 49
trials. This FOA utilizes the NIH (R01) Research Project
Grant award mechanism.
(301) 496-6761
Institute
PA-13-167
About
This FOA will utilize the NIH Research Grant (R21) funding
mechanism.
Funds/Direct Costs $275,000 direct costs over two years
allowed in any single year
Program Contact Silvia P. Torres
(240) 276-6322
silvia.torres@nih.gov
Institute
PA-13-246
About
This FOA utilizes the NIH (R21) award mechanism.
Funds/Direct Costs $275,000 direct costs for the entire
period of support, no more than
$200,000 may be requested in any
single year
(240) 276-5810
Institute
PA-13-247
About
This FOA utilizes the NIH Research Grants Award (R03)
Page 26 of 49
period of support, no more than
$50,000 in direct costs may be
(240) 276-5810
Institute
Solicitation of Assays for High Throughput
Screening (HTS) to Discover Chemical Probes
(R21)
PAR-12-059
About
encourages investigators to form collaborations with an
established academic, nonprofit, or commercial high
throughput screening (HTS) facility that has the requisite
expertise and experience to implement HTS-ready assays
for the discovery and development of small molecule
chemical probes. Through this FOA, the NCI is interested in
high throughput screens intended to identify small
clinical monitoring of treatment. Screens may be
biochemical, cellular or model organism-based. High
throughput screens for targets that address unmet needs in
cancer prevention, treatment or diagnosis are encouraged.
This FOA utilizes the NIH Exploratory/ Developmental
Research Grant (R21) award mechanism.
year
(301) 435-9147
Institute
Behavioral and Social Science Research on
Understanding and Reducing Health Disparities
(R21)
PA-13-288
About
The purpose of this FOA is to encourage behavioral and
social science research on the causes and solutions to
health and disabilities disparities in the U. S. population.
Health disparities between, on the one hand, racial/ethnic
populations, lower socioeconomic classes, and rural
residents and, on the other hand, the overall U.S.
population are major public health concerns. Emphasis is
placed on research in and among three broad areas of
action: 1) public policy, 2) health care, and 3)
disease/disability prevention. Particular attention is given to
reducing “health gaps” among groups. Applications that
utilize an interdisciplinary approach, investigate multiple
levels of analysis, incorporate a life-course perspective,
and/or employ innovative methods such as systems
science or community-based participatory research are
particularly encouraged. This FOA utilizes the NIH
Research Grants (R21) award mechanism.
period of support with no more than
$200,000 in direct costs in any
single year
Program Contact Rina Das
(240) 276-6184
dasr2@mail.nih.gov
Institute
Mechanisms, Models, Measurement and
Management in Pain Research (R21)
PA-13-119
About
New advances are needed in every area of pain research,
from the micro perspective of molecular sciences to the
macro perspective of behavioral and social sciences.
Although great strides have been made in some areas,
such as the identification of neural pathways of pain, the
experience of pain and the challenge of treatment have
remained uniquely individual and unsolved. Furthermore,
our understanding of how and why individuals transition to
a chronic pain state after an acute insult is limited.
Research to address these issues conducted by
interdisciplinary and multidisciplinary research teams is
strongly encouraged, as is research from
underrepresented, minority, disabled, or women
investigators. This program will use the NIH
Exploratory/Developmental (R21) grant mechanism.
Page 27 of 49
Funds/Direct Costs $275,000 direct costs over 2 years
6701 Democracy Boulevard
Suite 710
(301) 496-9623
mardens@mail.nih.gov
Institute
(R03)
PA-13-356
About
palliative care in geriatric populations. This R03
announcement specifically encourages projects primarily
aimed at collection of pilot data, demonstration of feasibility,
development of new methodology, or other goals of limited
scope requiring short-term support. This FOA emphasizes
studies in a variety of settings including ambulatory care,
hospitals (and specific sites within hospitals including
specialty wards, intensive care units and emergency
departments), assisted living facilities, and short- and longterm care facilities; however, hospice and end-of-life
settings are not included within the scope of this FOA, as
they are the subject of other NIH programs. Rather, this
FOA highlights research on palliative care in settings and at
time points earlier in geriatric patients' disease or disability
trajectories. Types of studies may include observational,
quasi-experimental, or pilot interventional studies using
primary data collection and/or secondary analyses.
Leveraging on-going cohorts, intervention studies,
networks, data and specimen repositories, and other
existing resources and infrastructure are encouraged. NCI’s
focus includes studies that identify factors that contribute to
tolerance of and adherence to cancer therapies and
improved enrollment and retention in clinical trials. This
FOA utilizes the NIH (R03) Small Grant Program award
mechanism.
(301) 496-6761
Institute
Bridging the Gap Between Cancer Mechanism and
Population Science (U01)
PAR-13-081
About
National Cancer Institute (NCI) and National Institute on
Alcohol Abuse and Alcoholism (NIAAA) invite applications
for projects that bridge biological mechanism to population
level scales. By incorporating insights and data from one
end of the cancer research spectrum into the framework of
the other, projects should be able to cross-validate data
gathered at different scales, and explore links between
basic biology, population science, and potential health
applications in treatment, prevention, diagnosis, and/or
screening. Proposed projects should pose a challenging
cancer research question that can be addressed by
connecting these two ends of the research spectrum that
would be difficult to address or explain through biological or
epidemiological investigation alone. Only a single cohesive
project integrating aspects from these two areas is allowed
in each application. This program will use the NIH (U01)
Research Project Cooperative Agreements award
mechanism.
Program Contact Jennifer Couch
(240) 276-6210
couchj@mail.nih.gov
Paul Calabresi Career Development Award for
Clinical Oncology (K12)
PAR-13-201
About
This funding opportunity announcement (FOA) encourages
applications for institutional research career development
(K12) programs from applicant organizations that propose
to promote the training and career development of clinical
trials researchers. The purpose of the Paul Calabresi
Career Development Award for Clinical Oncology (K12) is
to increase the number of clinicians (M.D.s, D.O.s,
Pharm.D.s, nurses with Ph.D.s or equivalent) and Ph.D.
scientists who are trained to design and test clinical
therapeutic research protocols (pilot/Phase I, Phase II, and
Phase III clinical trials), conduct patient-oriented cancer
therapeutic research in team research environments, and
to support the career development of investigators who
have made a commitment to focus their research
endeavors on patient-oriented research. This program will
use the NIH Mentored Clinical Scientist Development
Program (K12) award mechanism.
Page 28 of 49
Funds/Direct Costs $750,000 total per year
Budgetary Notes Direct costs are limited to $50,000 in
the initial year of new (Type 1) programs
Program Contact Mark Damico
6116 Executive Blvd
Bethesda, MD 20892
(240) 276-5630
damicomw@mail.nih.gov
investigate biological/genetic bases of cancer health
disparities. This FOA is also designed to aid and facilitate
the growth of a nationwide cohort of scientists with a high
level of basic research expertise in cancer health disparities
research and to provide resources for those investigators
that may need additional support on their path to
successfully compete for R01 funding in basic mechanistic
research in understanding cancer health disparities. This
FOA utilizes the NIH Exploratory/Developmental (R21)
grant mechanism.
Institute
Image-guided Drug Delivery in Cancer (R01)
PAR-13-185
year
Program Contact Phillip J. Daschner
(240) 276-6227
PD93U@nih.gov
About
National Cancer Institute (NCI) and National Institute of
Biomedical Imaging and Bioengineering (NIBIB) invite
applications for innovative research projects that are
focused on image-guided drug delivery (IGDD), including
real-time image guidance, monitoring, quantitative in vivo
characterizations and validation of delivery and response. It
will support research in development of integrated imagingbased platforms for multifunctional and multiplexed drug
delivery systems in cancer and other diseases, quantitative
imaging assays of drug delivery, and early intervention.
This FOA will use the NIH Research Project (R01) award
mechanism.
requested by R01 applicants but
costs should be appropriately
tailored to the proposed work
Program Contact Keyvan Farahani
6116 Executive Boulevard Suite 300
Bethesda, MD 20892
(240) 276-5921
farahank@mail.nih.gov
Institute
Exploratory/Developmental Grants Program for
Basic Cancer Research in Cancer Health
Disparities (R21)
PAR-12-094
About
grant applications from investigators interested in
conducting basic research studies into the biological
causes and mechanisms of cancer health disparities.
These awards will support pilot and feasibility studies,
development and testing of new methodologies, secondary
data analyses, and innovative mechanistic studies that
Institute
Exploratory Grant Award to Promote Workforce
Diversity in Basic Cancer Research (R21)
PAR-12-096
About
applications by investigators from diverse backgrounds
underrepresented in basic and biomedical cancer research.
The NIH recognizes a unique and compelling need to
promote diversity in the NIH-funded research workforce.
The purpose of this FOA is to improve the diversity of the
NCI-funded research workforce by supporting and
recruiting eligible investigators from groups that have been
shown to be underrepresented in the biomedical, clinical,
behavioral, and social sciences including individuals from
underrepresented racial and ethnic groups, individuals with
disabilities, and individuals from socially, culturally,
economically, or educationally disadvantaged backgrounds
that have recently and demonstrably inhibited their ability to
pursue a career in health-related research. This funding
opportunity will also provide a bridge to investigators that
have completed their research training and may need extra
time to develop a research project grant application. This
program utilizes the NIH Exploratory/Developmental (R21)
grant mechanism.
year
Program Contact Anil Wali, PhD
(240) 276-6183
walia@mail.nih.gov
Page 29 of 49
Institute
Basic Cancer Research in Cancer Health
Disparities (U01)
PAR-12-095
About
encourages grant applications from investigators interested
in conducting basic, mechanistic research into the
biologic/genetic causes of cancer health disparities. These
awards will support innovative studies designed to
investigate biological/genetic bases of cancer disparities,
and may include the development and testing of new
methodologies and models, secondary data analyses, and
mechanistic studies of identified biological factors
associated with cancer disparities, including those related
to basic research in prevention strategies. This FOA is also
designed to aid and facilitate the development of a
nationwide cohort of scientists with a high level of basic
research expertise in cancer health disparities research
who can develop resources and tools, such as
biospecimens, cell lines and methods that are necessary to
conduct basic research in cancer health disparities. This
FOA utilizes the NIH Research Project – Cooperative
Agreements (U01) grant mechanism.
Program Contact Phillip J. Daschner
(240) 276-6227
daschnep@mail.nih.gov
Utilizing the PLCO Biospecimens Resource to
Bridge Gaps in Cancer Etiology and Early
Detection Research (U01)
PAR-13-036
About
This Funding Opportunity Announcement (FOA), issued by
the National Cancer Institute (NCI), encourages the
submission of grant applications that propose to advance
research in cancer etiology and early detection biomarkers,
utilizing the advantages of the unique biorepository
resources of the NCI-sponsored Prostate, Lung, Colorectal,
and Ovarian Cancer (PLCO) Screening Trial. The PLCO
Biorepository offers high-quality, prospectively collected,
serial pre-diagnostic blood samples from the PLCOscreened arm participants, and a onetime collection of
buccal cells from the control arm participants. Available
data associated with the biospecimens includes
demographic, diet, lifestyle, smoking, screening results,
and clinical data. This FOA supports a wide range of
cancer research including, but not limited to, biochemical
and genetic analyses of cancer risk, as well as discovery
and validation of early detection biomarkers. The proposed
research project must involve use of PLCO biospecimens;
additionally, it should also take advantage of the unique
characteristics of the PLCO biospecimens. Research
projects that do not involve the use of PLCO biospecimens
will not be supported under this FOA. This FOA utilizes the
NIH Research Project Cooperative Agreements (U01)
award mechanism.
Program Contact Claire Zhu
(240) 276-7013
zhucla@mail.nih.gov
Institute
PA-13-166
About
This FOA will utilize the NIH Academic Research
Enhancement Award (R15) funding mechanism.
(301) 496-9623
wiriley@mail.nih.gov
Institute
Academic Research Enhancement Award (Parent
R15)
PA-13-313
About
The purpose of the Academic Research Enhancement
Award (AREA) program is to stimulate research in
educational institutions that provide baccalaureate or
advanced degrees for a significant number of the Nation's
research scientists, but that have not been major recipients
of NIH support. AREA grants create opportunities for
scientists and institutions, otherwise unlikely to participate
extensively in NIH research programs, to contribute to the
Page 30 of 49
Nation's biomedical and behavioral research effort. AREA
grants are intended to support small-scale research
projects proposed by faculty members of eligible, domestic
institutions, to expose students to meritorious research
projects, and to strengthen the research environment of the
applicant institution. This award utilizes the NIH (R15)
Academic Research Enhancement Award (AREA) grant
mechanism.
Funds/Direct Costs Up to $300,000 direct costs for
entire period of support
Program Contact Christopher L. Hatch
(240) 276-6454
ch29v@nih.gov
NCI Exploratory/Developmental Research Grant
Program (NCI Omnibus R21)
PAR-13-146
About
development of new research activities in all areas of
cancer research. The R21 mechanism is intended to
encourage exploratory and developmental research
projects by providing support for the early and conceptual
stages of these projects. These studies may involve
considerable risk but may lead to a breakthrough in a
particular area, or to the development of novel techniques,
agents, methodologies, models, or applications that could
have a major impact on a field of cancer research
(biomedical, behavioral, or clinical). This program will utilize
the NIH Research Grant (R21) mechanism.
Program Contact National Cancer Institute
(240) 276-6390
NCI Small Grants Program for Cancer Research
(NCI Omnibus R03)
PAR-14-007
About
This funding opportunity announcement (FOA), issued by
the National Cancer Institute (NCI), of the National
Institutes of Health (NIH) supports small research projects
on cancer that can be carried out in a short period of time
with limited resources. The R03 grant mechanism supports
different types of projects including pilot and feasibility
studies; secondary analysis of existing data; small, selfSCCC Research Administration
contained research projects; development of research
methodology; and development of new research
technology. This FOA utilizes the NIH Research Grants
(R03) funding mechanism.
Program Contact National Cancer Institute (NCI)
(240) 276-6390
PAR-12-229
About
transdisciplinary and translational research that will identify
specific biological or biobehavioral pathways through which
physical activity and/or weight control (either weight loss or
avoidance of weight gain) may affect cancer prognosis and
survival. Research applications must test the effects of
physical activity or weight control or both interventions on
biomarkers of cancer prognosis among cancer survivors
identified by previous animal or observational research,
which may include but are not limited to interventioninduced changes in sex hormones, insulin or insulin-like
growth factors or their binding proteins, insulin resistance,
glucose metabolism, leptin and other adipokines,
immunologic or inflammatory factors, oxidative stress and
DNA damage or repair capacity, angiogenesis, or
prostaglandins. This research will require transdisciplinary
approaches that bring together behavioral intervention
expertise, cancer biology, and other basic and clinical
science disciplines relevant to the pathways being studied.
This FOA will use the NIH Exploratory/Developmental
(R21) grant mechanism.
period of support with no more than
any single year
Program Contact Catherine M. Alfano
(240) 276-6736
Institute
Improving Diet and Physical Activity Assessment
(R21)
PAR-12-197
Page 31 of 49
About
encourages innovative research to enhance the quality of
measurements of dietary intake and physical activity.
Applications submitted under this FOA may include
development of: novel assessment approaches; better
methods to evaluate instruments; assessment tools for
culturally diverse populations or various age groups,
including children and older adults; improved technology or
applications of existing technology; statistical methods to
assess or correct for measurement errors or biases,
methods to investigate the multidimensionality of diet and
physical activity behavior through pattern analysis; or
integrated measurement of diet and physical activity along
with the environmental context of such behaviors. This
program utilizes the NIH Exploratory/Developmental (R21)
grant mechanism.
period of support, up to $200,000 in
year
Program Contact Amy Subar, PhD
4005
(301) 594-0831
subara@mail.nih.gov
NCI Mentored Patient-Oriented Research Career
Development Award to Promote Diversity (K23)
PAR-12-052
About
The purpose of this award is to support the career
development of investigators who have made a
commitment to focus their research endeavors on patientoriented cancer research (POR). The award supports
individuals with a health professional doctoral degree from
groups currently underrepresented on a national level in the
biomedical, clinical, behavioral, and social sciences. The
NCI recognizes a unique and compelling need to promote
diversity in the patient-oriented research workforce. This
FOA utilizes the NIH Research Career Development (K23)
grant mechanism.
Funds/Direct Costs Up to $100,000 per year for salary,
up to $30,000 per year in research
development costs
John
O. Ojeifo, MD, PhD, MBA
Program Contact
(240) 276-6186
ojeifojo@mail.nih.gov
NCI Transition Career Development Award to
Promote Diversity (K22)
PAR-12-062
About
The purpose of this award is to help ensure that a diverse
pool of highly trained scientists are available in adequate
numbers and in appropriate research areas to address the
nation's biomedical, behavioral, and clinical research
needs. Applications are invited from recipients of the NCI
Mentored Career Development Award to Promote Diversity,
or from advanced postdoctoral and/or newly independent
research scientists representative of groups that are
underrepresented in biomedical, behavioral, clinical, and/or
social sciences. This award will provide "protected time" for
recipients to develop and receive support for their initial
cancer research program. This FOA utilizes the NIH
Research Career Development (K22) grant mechanism.
Funds/Direct Costs $100,000 per year toward salary,
$50,000 per year for research
development costs
Program Contact Anil Wali, PhD
(240) 276-6183
walia@mail.nih.gov
Cancer Prevention, Control, Behavioral and
Population Sciences Career Development Award
(K07)
PAR-12-067
About
The purpose of the Cancer Prevention, Control, Behavioral
Sciences, and Population Sciences Career Development
Award is to support the career development of junior
investigators with research or health professional doctoral
degrees who want to become cancer-focused academic
researchers in cancer prevention, cancer control, or the
behavioral or population sciences. This Funding
Opportunity Announcement (FOA) utilizes the NIH
Academic Career Award (K07) mechanism.
Funds/Direct Costs $100,000 per year for salary,
$30,000 per year for research
development costs
Program Contact Susan Perkins
(240) 276-5630
perkinsu@mail.nih.gov
Page 32 of 49
NCI Established Investigator Award in Cancer
Prevention and Control (K05)
PAR-12-065
About
The purpose of the NCI Established Investigator Award in
Cancer Prevention and Control is to provide protected time
to senior investigators with exceptional mentoring records
and sustained, high levels of research productivity in
cancer prevention, cancer control, or the behavioral or
population sciences to devote to research and mentoring.
This Funding Opportunity Announcement (FOA) utilizes the
NIH Senior Scientist Award (K05) mechanism.
Funds/Direct Costs Salary support of 25% of the
institutional full-time staff
appointment base salary and
$25,000 per year direct costs
resulting from mentored activities
Program Contact Susan N. Perkins
(240) 276-5630
perkinsu@mail.nih.gov
NCI Transition Career Development Award (K22)
PAR-12-121
About
This Funding Opportunity Announcement (FOA) represents
the continuation of an NCI program to facilitate the
transition of investigators in mentored, non-independent
cancer research positions to independent faculty cancer
research positions. This goal is achieved by providing
protected time through salary and research support for the
initial 3 years of the first independent tenure-track faculty
position, or its equivalent. This FOA utilizes the NIH (K22)
Career Development Award mechanism.
Funds/Direct Costs $100,000 per year salary plus fringe
benefits, $50,000 in direct costs per
year for research and development
expenses
Program Contact Sonia Jakowlew, PhD
(240) 276-5630
jakowles@mail.nih.gov
Institute
NIH Pathway to Independence Award (Parent
K99/R00)
PA-14-042
About
The purpose of the NIH Pathway to Independence Award
(K99/R00) program is to increase and maintain a strong
cohort of new and talented, NIH-supported, independent
investigators. This program is designed to facilitate a timely
transition of outstanding postdoctoral researchers from
mentored, postdoctoral research positions to independent,
tenure-track or equivalent faculty positions, and to provide
independent NIH research support during the transition that
will help these individuals launch competitive, independent
research careers. The NCI accepts K99/R00 applications
that propose laboratory-based cancer research. This FOA
utilizes the NIH (K99/R00) Career Transition
Award/Research Transition Award funding mechanism.
Funds/Direct Costs $100,000 salary support plus fringe
per year and $30,000 research
support per year
Program Contact Michael Schmidt
(240) 276-5630
mschmidt@mail.nih.gov
Institute
(R21)
PAR-13-132
About
health decisions. This FOA utilizes the NIH Research Grant
(R21) mechanism.
Funds/Direct Costs $275,000 over an R21 two-year
period, up to $200,000 in direct
costs allowed in any single year
Program Contact Wen-Ying Sylvia Chou
(240) 276-6954
chouws@mail.nih.gov
Institute
Communication (R03)
PA-11-240
Page 33 of 49
About
NIH Small Grant Program (R03) award mechanism.
(301) 594-6546
li.zhu@nih.gov
Institute
Mentored Clinical Scientist Research Career
Development Award (Parent K08)
PA-14-046
About
The primary purpose of the NIH Mentored Clinical Scientist
Research Career Development Awards (K08) program is to
prepare qualified individuals for careers that have a
significant impact on the health-related research needs of
the Nation. This program represents the continuation of a
long-standing NIH program that provides support and
“protected time” to individuals with a clinical doctoral
degree for an intensive, supervised research career
development experience in the fields of biomedical and
behavioral research, including translational research. The
NCI K08 award provides support and “protected time” to
non-tenured clinician-scientists interested in mentored
basic and/or translational cancer research. Candidates
must have a clinical degree and practice clinically. This
FOA utilizes the NIH (K08) Clinical Investigator Award (CIA)
funding mechanism.
bennefits per year and $30,000
research support per year
Program Contact Sonia B. Jakowlew
(240) 276-5630
Institute
Midcareer Investigator Award in Patient-Oriented
Research (Parent K24)
PA-14-047
About
The NCI K24 award provides support and “protected time”
to Associate Professor level clinician-scientists to expand
their patient-oriented cancer research and to mentor junior
clinician-scientists. The applicant must be the Principal
Investigator (PI) of an R01, or R01-like, peer-reviewed
cancer-focused research grant at the time of application.
This research grant must be active for at least two
remaining years at the time of K24 application. The PI is
expected to maintain such research grant support during
the project period. This FOA utilizes the NIH (K24)
Midcareer Investigator Award in Patient-Oriented Research
funding mechanism.
Funds/Direct Costs Salary support up to the maximum
legislative salary cap plus fringe
benefits per year for 25-50% effort
and research support up to $50,000
per year
Program Contact Susan E. Lim
(240) 276-5630
lims@mail.nih.gov
Institute
Mentored Quantitative Research Development
Award (Parent K25)
PA-14-048
About
The purpose of the Mentored Quantitative Research Career
Development Award (K25) is to attract to NIH-relevant
research those investigators whose quantitative science
and engineering research has thus far not been focused
primarily on questions of health and disease. The K25
award will provide support and “protected time” for a period
of supervised study and research for productive
professionals with quantitative (e.g., mathematics,
statistics, economics, computer science, imaging science,
informatics, physics, chemistry) and engineering
backgrounds to integrate their expertise with NIH-relevant
research. The NCI K25 is aimed at fostering the research
careers of scientists in quantitative disciplines who are
committed to developing research programs in
understanding human biology and human disease as it
relates to the etiology, pathogenesis, prevention, diagnosis,
and treatment of cancer. NCI requires that the K25
applicant identify a mentor whose research is cancer
relevant. This FOA utilizes the NIH (K25) Mentored
Quantitative Research Career Development Award funding
Page 34 of 49
mechanism.
Program Contact Sonia B. Jakowlew
(240) 276-5630
Pilot Studies in Pancreatic Cancer (R21)
PA-11-297
About
encourages the submission of applications that propose to
promote innovative research across multiple disciplines for
a better understanding of the biology, etiology, detection,
prevention, and treatment of pancreatic cancer. This FOA
focuses on pilot projects in early and conceptual stages
that could provide a basis for more extended research.
These studies may involve considerable risk but should
have the potential to generate highly innovative findings or
technical/methodological improvements that could have a
major impact on the field of pancreatic cancer research.
This FOA utilizes the Exploratory/Developmental Research
Grant (R21) Award mechanism.
period of support, up to $200,000 in
year
Program Contact Mukesh Verma, PhD
5140
(301) 594-7344
vermam@mail.nih.gov
Institute
Research on Ethical Issues in Biomedical, Social,
and Behavioral Research (R03)
PA-11-181
About
(FOA) is to support applications that propose to study high
priority bioethical challenges and issues associated with the
types of biomedical, social and behavioral research
supported by the participating NIH Institutes/Centers. The
following specific bioethics topics will be given the highest
priority for consideration. These are organized into seven
categories: 1) ethical considerations of new and emerging
technologies; 2) research study design issues; 3) issues
associated with therapeutic misconception and the
interface between treatment and research; 4) research
involving vulnerable populations and urgent situations; 5)
research with existing specimens, data, and health
information; 6) dissemination and translation of research
findings; and 7) oversight of research. The NCI is
particularly interested in studies in evaluation and/or
mitigation strategies for ethical challenges in cancer
genome studies. This FOA will utilize the NIH Small Grant
Program (R03) award mechanism.
Program Contact Kim Witherspoon
(240) 276-6141
kw265c@nih.gov
Institute
Translational Research at the Aging/Cancer
Interface (TRACI) (R21)
PA-12-135
About
encourages translational research proposals in the
overlapping areas of human aging and cancer, linking basic
and clinical research relevant to the care of older cancer
patients through both bench-to-bedside and bedside-tobench approaches. Ultimately, information from the
research supported by this initiative should improve the
health and well-being of elderly patients at risk for, or
diagnosed with, cancer and decrease the functional
impairment and morbidity associated with cancer in this
population. This FOA utilizes the NIH Exploratory/
Developmental (R21) grant mechanism.
year
(301) 496-6761
eldadahb@nia.nih.gov
Institute
Communication (R21)
PA-11-239
Page 35 of 49
About
NIH Exploratory/Developmental Research Grant Award
(R21) mechanism.
period of support
(301) 594-6546
li.zhu@nih.gov
Institute
Dissemination and Implementation Research in
Health (R03)
PAR-13-056
About
encourages investigators to submit research grant
applications that will identify, develop, and refine effective
and efficient methods, structures, and strategies to
disseminate and implement research-tested health
behavior change interventions and evidence-based
prevention, early detection, diagnostic, treatment, and
quality of life improvement services into public health and
clinical practice settings. This FOA utilizes the NIH Small
Research Grant (R03) award mechanism.
Funds/Direct Costs Budgets for direct costs of up to
$50,000 per year and a project
duration of up to two years may be
requested for a maximum of
$100,000 direct costs over a twoyear project period
Program Contact David A. Chambers
(301) 443-3747
dchamber@mail.nih.gov
Identifying Non-coding RNA Targets for Early
Detection of Cancer (R21)
PA-12-214
About
encourages research projects on non-coding RNAs
(ncRNAs) and their targets in preneoplastic lesions and
early stage cancers. This FOA also encourages research
projects to assess the usefulness of stable microRNAs
(miRNAs) and ncRNAs to predict progression to cancer
and as biomarkers for early cancer detection and
screening. Building on both basic and biomarker research
on microRNAs (miRNA), this FOA will further promote
research on all classes of ncRNAs and support the
translation of stable miRNAs into cancer screening or
diagnostic tests. This Funding Opportunity Announcement
(FOA) utilizes the NIH Exploratory/Developmental (R21)
grant mechanism.
year
Program Contact Wendy Wang
3138
(301) 594-7607
wangw@mail.nih.gov
Biomarkers for Early Detection of Hematopoietic
Malignancies (R21)
PA-12-220
About
encourages research projects for the development and
validation of biomarkers for: a) early detection, prediction of
progression, and recurrence of hematopoietic
malignancies, especially in high-risk individuals; and, b) for
risk assessment of primary and secondary hematopoietic
malignancies. This FOA also encourages the development
and improvement of specific technologies and methods for
quantitative detection of novel biomarkers associated with
hematopoietic malignancies. This program utilizes the NIH
period of suppport, up to $200,000
year
Program Contact Lynn Sorbara
3137
(301) 435-0584
lynns@mail.nih.gov
Page 36 of 49
Institute
Pilot and Feasibility Clinical Research Studies in
Digestive Diseases and Nutrition (R21)
PA-12-139
Institute
Exploratory/Developmental Clinical Research
Grants in Obesity (R21)
PA-12-179
About
encourages pilot and feasibility clinical and epidemiological
research studies of new therapies or means of health
promotion and prevention of digestive and liver diseases
and nutritional disorders associated with digestive and liver
diseases. This FOA utilizes the NIH Exploratory/
Developmental (R21) grant mechanism.
About
This FOA encourages research grant applications from
institutions/organizations that propose to conduct
exploratory/developmental clinical studies that will
accelerate the development of effective interventions for
prevention or treatment of overweight or obesity in adults
and/or children. Exploratory epidemiological research with
a goal of informing translational/clinical research will also
be supported within this program. The types of research
applications which NCI is interested in supporting include
human intervention studies utilizing bioactive components
(e.g., tea polyphenols, calcium) or variation in diet
composition strategies that evaluate weight change in
populations of interest to NCI. Such populations include
individuals with a genetic propensity for cancer as well as
those with cancer or those at risk for recurrence of cancer.
This FOA utilizes the NIH Exploratory/Developmental (R21)
grant mechanism.
year
Program Contact Maria Agelli, MD, MS, FACPM
3104
(301) 451-3993
ma215e@nih.gov
Institute
Mentored Patient-Oriented Research Career
Development Award (Parent K23)
PA-14-049
About
The purpose of the NIH Mentored Patient-Oriented
Research Career Development Award (K23) is to support
the career development of individuals with a clinical
doctoral degree who have made a commitment to focus
their research endeavors on patient-oriented research. The
NCI K23 award provides support and “protected time” to
non-tenured clinician-scientists interested in mentored
patient-oriented cancer research. Candidates must have a
clinical degree and practice clinically. Documentation of
active licensure must be included in the application. This
FOA utilizes the NIH (K23) Mentored Patient-Oriented
Research Career Development Award funding machanism.
Program Contact Susan E. Lim
(240) 276-5630
lims@mail.nih.gov
Period of Support Maximum of 2 years
period of support, with up to
any single year
Program Contact Sharon A. Ross, PhD
3175
(301) 594-7547
rosssha@mail.nih.gov
Institute
Research on Ethical Issues in Biomedical, Social,
and Behavioral Research (R21)
PA-11-182
About
(FOA) is to support applications that propose to study high
priority bioethical challenges and issues associated with the
types of biomedical, social, and behavioral research
supported by the participating NIH Institutes/Centers. The
following specific bioethics topics will be given the highest
priority for consideration. These are organized into seven
categories: 1) ethical considerations of new and emerging
technologies; 2) research study design issues; 3) issues
associated with therapeutic misconception and the
interface between treatment and research; 4) research
involving vulnerable populations and urgent situations; 5)
Page 37 of 49
research with existing specimens, data, and health
information; 6) dissemination and translation of research
findings; and 7) oversight of research. The NCI is
particularly interested in studies on evaluation and/or
mitigation strategies for ethical challenges in cancer
genome studies. This FOA utilizes the NIH
Exploratory/Developmental Research Grant Award (R21)
mechanism.
year
Program Contact Shane Woodward
(240) 276-6303
dwards@mail.nih.gov
Validation of Molecular Diagnostics to Predict
Patient Outcomes Using Specimens from MultiSite Cancer Trials (R21)
PA-12-014
About
encourages the submission of applications to validate the
clinical utility of new molecular diagnostics for determining
prognosis or predicting response to therapy or toxicity for
cancer. This program will support pilot research projects to
improve clinical decision-making in the care of cancer
patients and as such will support studies that use tumor
specimens linked to specific treatment and clinical outcome
information. This FOA is not appropriate for molecular
diagnostics discovery projects. This FOA will utilize the NIH
Exploratory/Developmental Grant (R21) mechanism.
period of support, with no more than
$200,000 requested in any single
year
Program Contact Magdalena Thurin, PhD
(301) 496-1591
thurinm@mail.nih.gov
Institute
Mechanisms of Alcohol-Associated Cancers (R21)
PA-12-147
About
This Funding Opportunity Announcement invites
applications from researchers with broad ranges of
expertise to study the mechanisms by which alcohol
increases cancer risk. Target sites for alcohol-related
carcinogenesis include the oral cavity, pharynx, esophagus,
larynx, breast, liver, and colon. A better understanding of
the molecular basis by which alcohol increases cancer risk
could lead to improved therapeutic approaches and
preventative strategies and would provide guidance on safe
levels of alcohol consumption. The goal of this program
announcement is to stimulate a broad range of research
into the mechanisms by which alcohol contributes to
carcinogenesis. This FOA utilizes the NIH Research Grant
(R21) award mechanism.
Funds/Direct Costs $275,000 direct costs for the entire
year
Program Contact M. Katherine Jung
(301) 443-8744
jungma@mail.nih.gov
NEW
Institute
Extended Development, Hardening and
Dissemination of Technologies in Biomedical
Computing, Informatics and Big Data Science
(R01)
PA-14-156
About
The goal of this program announcement is to support the
extended development, maintenance, testing, evaluation,
hardening and dissemination of existing biomedical
software. The NIH is interested in promoting a broad base
of research and development of technologies in biomedical
computing, informatics, and Big Data Science that will
support rapid progress in areas of scientific opportunity in
biomedical research. It is expected that this research and
development is conducted in the context of important
biomedical and behavioral research problems and that
domain researchers are consulted to make sure that the
software is relevant to users. As such, applications are
intended to develop enabling technologies that could apply
to the interests of most NIH Institutes and Centers and
range from basic biomedicine and including research to all
relevant organ systems and diseases. Major themes of
research include collaborative environments; data
integration; analysis and modeling methodologies; and
novel computer science and statistical approaches. New
opportunities are also emerging as large and complex data
sets are becoming increasingly available to the research
community. The proposed work should apply best
practices and proven methods for software design,
construction, and implementation to extend the applicability
of existing technologies in biomedical computing,
informatics and big data science to a broader biomedical
research community. This FOA utilizes the NIH (R01)
Research Project award mechanism.
Page 38 of 49
Program Contact NIH Grant Resources
(301) 435-0714
GrantsInfo@nih.gov
Fundamental Mechanisms of Affective and
Decisional Processes in Cancer Control (U01)
PAR-14-067
About
projects to generate fundamental knowledge of affective
processes. Basic affective science projects should have
key downstream consequences for single (e.g., genetic
testing consent) and multiple (e.g., adherence to oral
chemotherapy regimen) event decisions and behaviors
across the cancer prevention and control continuum. The
FOA is expected to encourage scientific disciplines that
have not traditionally conducted cancer research such as
affective and cognitive neuroscience, decision science, and
consumer science to elucidate perplexing and understudied
problems in basic affective and decision sciences with
promise of having downstream implications for cancer
prevention and control science. This program utilizes the
NIH (U01) Research Project Cooperative Agreements
award mechanism.
Program Contact Rebecca A. Ferrer
(240) 276-6914
ferrerra@mail.nih.gov
NCI Mentored Research Scientist Development
Award to Promote Diversity (K01)
PAR-12-050
About
The purpose of this award is to provide support and
“protected time” (three, four, or five years) for an intensive,
supervised career development experience in the
biomedical, behavioral, or clinical sciences leading to
research independence. Awards are not renewable and
they are not transferable from one principal investigator (PI)
to another. Applications are invited from individuals
representative of groups that have been shown to be
underrepresented in health-related science, who have been
recipients of an NIH Research Supplement to Promote
Diversity Award, any Ruth L. Kirschstein National Research
Service Award (individual F31/F32 or institutional T32), or
can demonstrate that they have been supported in a
mentored capacity within any research grant equivalent to
an NIH peer-reviewed research grant (e.g., American
Cancer Society [ACS] research grant). The overarching
goal of this Funding Opportunity Announcement (FOA) is to
diversify and expand the pool of independent and talented
cancer research investigators. This FOA utilizes the NIH
Mentored Research Scientist Development Award (K01)
mechanism.
Funds/Direct Costs Up to $100,000 per year toward
salary and $30,000 per year toward
research development costs
Budgetary Notes 8% indirect costs are allowed
Program Contact John Ojeifo
(240) 276-6186
NCI Mentored Clinical Scientist Research Career
Development Award to Promote Diversity (K08)
PAR-12-051
About
The primary purpose of this program is to prepare
individuals for careers that have a significant impact on the
health-related research needs of the nation. This program
represents the continuation of a long-standing NIH program
that provides support and protected time to individuals with
a clinical doctoral degree for an intensive, supervised
research career development experience in the fields of
biomedical and behavioral research, including translational
research. This NCI-sponsored K08 award is specifically
designed to promote career development of clinical
scientists from diverse backgrounds that have been shown
to be underrepresented in health-related science and for
those who are committed to a career in basic biomedical,
behavioral or translational cancer research, including
research on cancer health disparities. This FOA utilizes the
NIH Research Career Development (K08) grant
mechanism.
Funds/Direct Costs Up to $100,000 per year toward
salary plus benefits and up to
$30,000 toward research
development costs
Program Contact John Ojeifo
(240) 276-6186
Request for Applications (RFA)
Page 39 of 49
Research Answers to NCI's Provocative
Questions - Group C (R21)
RFA-CA-13-021
FOA are expected to generate findings and data that are
directly relevant to inform the FDA's regulation of the
manufacture, distribution, and marketing of tobacco
products to protect public health. This FOA will utilize the
NIH Research Grants (R21) award mechanism.
Funds/Direct Costs $275,000 direct costs for an entire
period of support
Program Contact Stephanie Land
(240) 276-6946
stephanie.land@nih.gov
About
The National Cancer Institute (NCI) innovative research
projects are designed to solve specific problems and
paradoxes in cancer research identified by the NCI
Provocative Questions initiative. These problems and
paradoxes phrased as questions are not intended to
represent the full range of NCI's priorities in cancer
research. Rather, they are meant to challenge cancer
researchers to think about and elucidate specific problems
in key areas of cancer research that are deemed important
but have not received sufficient attention. Some of these
"Provocative Questions" (PQs) stem from intriguing but
older, neglected observations that have never been
adequately explored. Other PQs are built on more recent
findings that are perplexing or paradoxical, revealing
important gaps in current knowledge. Finally, some PQs
reflect problems that traditionally have been thought to be
intractable but that now may be open to investigations
using new strategies and recent technical advances. Each
research project proposed in response to this FOA must be
focused on solving one particular research problem defined
by one specific PQ selected from the list of Provocative
Questions. This FOA will utilize the NIH
Exploratory/Developmental (R21) award mechanism.
period of support
No
more than $200,000 in direct costs
Budgetary Notes
are allowed in any single year
Program Contact Emily J. Greenspan
(301) 496-1045
greenspanej@mail.nih.gov
Institute
Tobacco Control Regulatory Research (R21)
RFA-OD-13-010
About
(FOA) is to encourage biomedical, behavioral, and social
science research that will inform the development and
evaluation of regulations on tobacco product
manufacturing, distribution, and marketing. Research
projects must address the research priorities related to the
regulatory authority of the Food and Drug Administration
(FDA) Center for Tobacco Products (CTP) as mandated by
the Family Smoking Prevention and Tobacco Control Act
(FSPTCA), Public Law 111-31. Research results from this
Questions- Group E (R01)
RFA-CA-13-024
About
Questions. This FOA will use the NIH Research Project
but need to reflect the actual
needs of the proposed project
(301) 496-1045
Page 40 of 49
Questions- Group D (R21)
RFA-CA-13-023
About
Questions. This FOA will use the NIH NIH Exploratory/
Developmental (R21) award mechanism.
period of support
No
more than $200,000 in direct costs
Budgetary Notes
(301) 496-1045
Questions- Group D (R01)
RFA-CA-13-022
About
Questions. This FOA will use the NIH Research Project
(301) 496-1045
Questions- Group E (R21)
RFA-CA-13-025
About
Questions. This FOA will use the NIH Exploratory/
Page 41 of 49
period of support
(301) 496-1045
Questions - Group C (R01)
RFA-CA-13-020
About
Questions. This FOA will utilize the NIH Research Project
(301) 496-1045
Questions- Group B (R21)
RFA-CA-13-019
About
Questions. This FOA will utilize the NIH Exploratory/
period of support
are allowed in any single year
(301) 496-1045
Research Answers to NCI’s Provocative
Questions- Group B (R01)
RFA-CA-13-018
About
Page 42 of 49
Questions. This FOA will utilize the NIH Research Project
Questions - Group A (R01)
RFA-CA-13-016
(301) 496-1045
Questions - Group A (R21)
RFA-CA-13-017
About
The National Cancer Institute (NCI) invites innovative
research projects designed to solve specific problems and
Questions. This FOA will utilize the NIH
period of support
(301) 496-1045
About
The National Cancer Institute (NCI) invites innovative
research projects designed to solve specific problems and
Questions. This FOA utilizes the NIH Research Grants
(301) 496-1045
Institute
RFA-OD-13-011
About
Page 43 of 49
(240) 276-6946
Early-Stage Innovative Molecular Analysis
Technology Development for Cancer Research
(R21)
RFA-CA-14-003
About
This Funding Opportunity Announcement (FOA) solicits
grant applications proposing exploratory research projects
focused on the inception and development of early stage,
highly innovative, technologies for the molecular or cellular
analysis of cancer. Emerging technologies with significant
transformative potential that have not yet been explored in
a cancer-relevant use may also be considered. An
emerging technology is defined (for the purpose of this
FOA) as one that has passed the initial developmental
stage, but has not yet been evaluated within the context of
cancer-relevant use intended in the application and
requires significant modification for the proposed
application to establish feasibility. The emphasis of this
FOA is on molecular analysis technologies with a high
degree of technical innovation with the potential to
significantly affect and transform investigations exploring
the molecular and cellular bases of cancer. If successful,
these technologies would accelerate and/or enhance
research in the areas of cancer biology, early detection and
screening, clinical diagnosis, treatment, control,
epidemiology, and/or cancer health disparities.
Technologies proposed for development may be intended
to have widespread applicability but must be based on
molecular and/or cellular characterizations of cancer. This
FOA utilizes the NIH (R21) award mechanism for
exploratory/developmental pilot projects.
period of support
Program Contact Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov
Validation and Advanced Development of
Emerging Molecular Analysis Technologies for
Cancer Research (R33)
RFA-CA-14-004
"http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14004.html"
About
grant applications proposing research projects on the
advanced development of emerging molecular and cellular
analysis technologies and technical/analytical validation in
an appropriate cancer-relevant biological system. An
emerging technology is defined as one that has passed the
pilot developmental stage and shows promise, but has not
yet been significantly evaluated within the context of its
intended use. If successful, these technologies would
accelerate research in cancer biology, cancer treatment
and diagnosis, early detection and screening, cancer
control and epidemiology, and/or cancer health disparities.
This FOA solicits projects where proof-of-principle of the
proposed technology or methodology has been established
and supportive preliminary data are available. Projects
proposed to this FOA should reflect the potential to produce
a molecular analysis technology with a major impact in a
broad area of cancer-relevant research. Projects proposing
to use established technologies where the novelty resides
in the biological or clinical question being pursued are not
appropriate for this solicitation and will not be reviewed.
This FOA utilizes the NIH (R33) Exploratory/Developmental
Research Grant award mechanism.
(301) 547-9980
Early-Stage Development of Innovative
Technologies for Biospecimen Science (R21)
RFA-CA-14-005
"http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14005.html"
About
grant applications proposing technically innovative
feasibility studies focused on early-stage development of
technologies that address issues related to pre-analytical
variations in the collection, processing, handling, and
storage of cancer-relevant biospecimens or their
derivatives. The overall goal is to develop technologies
capable of interrogating and/or maximizing the quality and
utility of biospecimens or samples derived from those
biospecimens for downstream analyses. This FOA will
support the development of tools, devices, instrumentation,
and associated methods to assess sample quality,
Page 44 of 49
preserve/protect sample integrity, and establish verification
criteria for quality assessment/quality control and handling
under diverse conditions. These technologies are expected
to potentially accelerate and/or enhance research in cancer
biology, early detection, screening, clinical diagnosis,
treatment, epidemiology, and cancer health disparities, by
reducing pre-analytical variations that affect biospecimen
sample quality. All projects must include quantitative
milestones (i.e., technical metrics that determine whether
the specific aims have been accomplished). This FOA
utilizes the NIH (R21) Exploratory/Developmental Research
Grant award mechanism.
(301) 547-9980
period of support
(301) 547-9980
Validation and Advanced Development of
Emerging Technologies for Biospecimen Science
(R33)
RFA-CA-14-006
About
grant applications proposing technically innovative
feasibility studies focused on the advanced development
and validation of cancer-relevant technologies that address
issues related to pre-analytical variations in the collection,
processing, handling, and storage of biospecimens or their
derivatives. The overall goal is to develop technologies
capable of interrogating and/or maximizing the quality and
utility of biospecimens or their derived samples for
downstream analyses. This FOA will support the
development of tools, devices, instrumentation, and
associated methods to assess sample quality,
preserve/protect sample integrity, and establish verification
criteria for quality assessment/quality control and handling
under diverse conditions. This FOA solicits R33
applications for projects where proof-of-principle of the
proposed technology or methodology has already been
established and supportive preliminary data are available.
Projects proposing to use established technologies where
the novelty resides in the biological or clinical question
being pursued are an example of a topic not appropriate for
this solicitation and will not be reviewed. This FOA utilizes
the NIH (R33) Exploratory/Developmental Research Grant
award mechanism.
Institute
RFA-OD-13-012
About
(240) 276-6946
Page 45 of 49
Deadline: Applications accepted on an ongoing basis
"http://www.genzyme.com/Responsibility/Grants-andGiving/Applying-for-a-Grant.aspx"
About
The research funding process for Accelerate Brain Cancer
Cure (ABC2) is designed to move the best ideas into the
clinic as soon as possible. The sponsor believes that
innovation and solid research should not linger in research
labs. Proposals need to identify a clear problem and lay out
a clear roadmap to find a solution. Since speed counts,
rather than simply issuing a yearly request for proposals
(RFP), the sponsor constantly scouts research labs for
advances which can be translated into new treatments for
patients. ABC2 funds projects at each stage of the
therapeutic development pipeline to ensure promising leads
are advanced as quickly as possible.
About
In alignment with Genzyme's commitment to innovation in
science and areas of unmet medical need, Genzyme
supports grants and charitable donations in the following
areas: Rare genetic diseases; Thyroid Cancer;
Cardiovascular; and Multiple Sclerosis.
Not specified
Period of Support
Funds/Direct Costs Not specified
Program Contact David Sandak
(202) 419-3140
david.sandak@abc2.org
MULTIPLE DATES / OTHER
DEADLINES
Genzyme
Genzyme Corporation Grants
Unspecified
Period of Support
Program Contact Genzyme
(877) GENZYME
x14040
Solving Kids' Cancer
Clinical Project Grant Awards
Deadline: Letters of Intent accepted on an ongoing basis
"http://solvingkidscancer.org/work/grants"
Solving Kids Cancer (SKC)
Therapeutic Development Initiative (TDI)
Deadline: Proposals are accepted on an ongoing basis
"http://solvingkidscancer.org/work/grants"
About
The Therapeutic Development Initiative(TDI) is Solving Kids
Cancer's strategic program to support the investigation of
novel treatments through clinical studies to answer
important research questions as quickly, effectively, and
economically as possible. The TDI supports clinical testing
of promising therapies that may significantly and
fundamentally improve treatment for children with pediatric
cancer. While SKC values pre-clinical research, only
clinical studies are supported via the TDI program. Final
pre-clinical work that is requisite to the submission of a
protocol may be considered in certain circumstances. The
clinical study must focus on neuroblastoma, pediatric
central nervous system tumors and/or sarcomas.
Period of Support
Funds/Direct Costs
Budgetary Notes
Program Contact
2 years
Up to $600,000 direct costs for
entire period of support
Indirect costs are not allowed
Solving Kids Cancer
(212) 588-6624
grants@solvingkidscancer.org
Accelerate Brain Cancer Cure
Research Grants
Deadline: Proposals accepted on an ongoing basis
"http://www.abc2.org/smarter-research/how-we-fund"
About
The spirit of this request is to inspire the scientific research
community to submit their best ideas for therapeutic
development to improve survivorship for children with
neuroblastoma, pediatric central nervous system tumors
and sarcomas. The sponsor seeks testable questions and
ideas about therapies for these childhood cancers that may
provide therapeutic solutions where currently there are
none. The sponsor's goal is to fund “dream” ideas that are
not currently being funded through existing sources.
Period of Support
Funds/Direct Costs
Budgetary Notes
Program Contact
Up to 2 years
$25,000 to $300,000 direct costs
over entire period of support,
depending on the nature of the
proposed project
No indirect costs are allowed
Solving Kids' Cancer
(212) 588-6624
grants@solvingkidscancer.org
International Waldenstrom's Macroglobulinemia
Foundation
Research Grant Program
"http://www.iwmf.com/research/applying-for-a-grant.aspx"
About
The International Waldenstrom's Macroglobulinemia
Foundation (IWMF) Research Grant Program offers
support for basic scientific research that will further
knowledge of the cause, diagnosis, treatment and cure for
the disease Waldenstrom's macroglobulinemia.
Page 46 of 49
Period of Support
Funds/Direct Costs
Program Contact
Up to 2 years
Up to $200,000 over entire period of
support
Guy Sherwood
(941) 927-4963
guysherwood@comcast.net
Period of Support
Funds/Direct Costs
Budgetary Notes
Program Contact
General Motors Foundation
Research Grants
Up to 2 years
Not specified
Grants are not intended to support
the salary of the investigator and
indirect costs are not allowed
Liddy Shriver Sarcoma Initiative
(914) 762-3251
info@sarcomahelp.org
"http://www.gm.com/company/aboutGM/gm_foundation.html
"
Pediatric Low Grade Astrocytoma (PLGA)
Foundation
Brain Tumor Research Grants
About
The General Motors Foundation (GMF) supports
organizations working to further research related to the
causes, prevention, and treatment of various diseases such
as cancer, heart disease, and diabetes. Primary
consideration is given to requests that meet the following
criteria:
• Exhibit a clear purpose and defined need in one of GMF's
areas of support
• Recognize innovative approaches in addressing the
defined need
• Demonstrate an efficient organization and detail the
organization’s ability to follow through on their proposal
Deadline: Letters of Intent accepted on an ongoing basis
"http://akidsbraintumorcure.org/medical-research-onchildhood-brain-tumors/apply-for-a-plga-sponsored-grant/"
Up to 1 year
Period of Support
Indirect costs are not allowed
Budgetary Notes
Program Contact General Motors Foundation
cgsupport@cybergrants.com
Liddy Shriver Sarcoma Initiative
Research Grants Program
"http://sarcomahelp.org/sarcoma-research.html?tpm=2_3"
About
The sponsor funds basic research seed grants in sarcoma.
The sponsor is interested in a wide range of research.
Some examples are: understanding the molecular biology
of sarcomas; exploring "molecular targets" for new sarcoma
therapies; studying chromosomal translocations, the
oncogenes they generate and their role in sarcoma
development; translational studies; studying vaccines,
monoclonal antibodies, and mTOR inhibitors; studying the
use of nanotechnology in the diagnosis and treatment of
sarcomas; understanding the basis of radiation-induced
sarcoma; modeling of the process of metastases; exploring
the differences in the development of sarcomas in children,
adolescents, young adults and adults; and research
directed at the early detection and diagnosis of sarcoma.
Grants can be used for the development of models,
conducting experiments, development of sarcoma tissue
registries, and similar activities involved in support of
research into the causes, origins, development, molecular
biology, diagnosis, and treatment of sarcoma. The sponsor
does not fund clinical trials.
About
The number one priority of the Pediatric Low Grade
Astrocytoma (PLGA) Foundation is to act as a catalyst for
researchers world-wide to turn their attention to the area of
PLGA brain tumors and to award research grants for the
most promising programs and studies which will lead to a
better understanding of the causes of PLGA as well as the
creation of more effective treatments and a cure for
pediatric low grade (grades 1 and 2) astrocytoma tumors.
Proposals related to basic and translational projects that
can advance understanding of the underlying biology of the
development and treatment of PLGA tumors will be
considered. Investigators in the early years of their careers
are encouraged to apply.
Up to 3 years
Period of Support
Program Contact Pediatric Low Grade Astrocytoma
Foundation (PLGA)
(914) 762-3494
contact@akidsbraintumorcure.org
Fanconi Anemia Research Fund, Inc.
Head and Neck Carcinogenesis Grant
"http://www.fanconi.org/index.php/research/grant_applicatio
ns"
About
This funding opportunity supports work focused on the
molecular pathogenesis, diagnosis, and treatment of head
and neck squamous cell carcinoma in patients with Fanconi
anemia (FA). The sponsor will consider the following in
making funding decisions: responsiveness of the
application to the problem of head and neck cancer in
Fanconi anemia patients; scientific merit of the proposed
project as determined by peer review: the degree to which
the results might advance the field, the degree to which the
results might improve disease control, the degree to which
the results might improve the health and well-being of FA
patients; and availability of funds.
Page 47 of 49
Not specified
Period of Support
Program Contact Fanconi Anemia Research Fund, Inc.
1801 Willamette Street, Suite 200
Eugene, OR 97401
(541) 687-4658
info@fanconi.org
Intramural Funding Opportunities
UM/Scientific Awards Committee
Interdisciplinary Team Science (ITS) Pilot Program
Grants
"http://uresearch.miami.edu/default.asp?p=265"
About
Provide up to $50,000 - a maximum of $75,000 in direct
research costs to provide resources to assist faculty
members in developing new research projects with an
emphasis on interdisciplinary science, according to the
following criteria: 1) research projects should involve the
synergistic collaboration of two or more investigators,
ideally from different disciplines or areas of study; 2)
research projects should represent new and distinct areas
where the applicant research team has no current funding
or publications; 3) new and/or expanded direction(s) for
existing research programs, where such directions are
made possible by collaboration. The ultimate goal for the
ITS Pilot Program is to facilitate the creation of new project
teams who can develop new interdisciplinary research
programs and obtain extramural funding for a Team
Science Proposal, Program Project and/or Center grants.
Pilot Study Grants
"http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir
=asc&fo_page=1&fo_search=1&item=20&p=43&pid=160&
m=fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo
_isls=A*"
About
Pilot Study Grants provide support to assist faculty in jumpstarting new research areas, including new and distinct
research areas where the applicant has no existing funding
or publications, as well as new direction(s) for existing
research programs in which the applicant has past
experience but no current funding. All full time faculty at the
Miller School of Medicine are eligible. Preference will be
given to faculty who have been granted their appointments
at least three years before the SAC meeting at which their
applications are to be considered. Applications are due on
the 18th of each month (July – March).
Period of Support
Funds/Direct Costs
Program Contact
Up to 1 year
Up to $20,000 in direct research
costs
Karen Del Rio
(305) 243-5370
kdelrio@.miami.edu
Bridge Funding Grants
"http://uresearch.miami.edu/?p=43&pid=160&m=fundingph&
mid=2&item=21"
Funds/Direct Costs Up to $75,000 direct costs
Program Contact Karen Del Rio
(305) 243-5370
kdelrio@miami.edu
About
Bridge Funding Grants provide support to assist faculty in
maintaining their research program in the event of a
funding lapse during the process of applying for additional
extramural funding. Applications are due on the 18th of
each month (July – March).
Post-A1 Re-Tooling Grants
Period of Support
Funds/Direct Costs
"http://uresearch.miami.edu/default.asp?p=265"
Budgetary Notes
About
The Post-A1 Re-Tooling Grants assist faculty who are no
longer eligible for Bridge funding, but will support them
when their NIH Research Grant (R-series) A1 (revised)
application is not funded. This transition phase will allow
faculty to "re-tool" their specific aims and research plan for
a new NIH submission. Applications are due on the 18th of
each month (July – March).
Period of Support
Funds/Direct Costs
Program Contact
Program Contact
Up to 1 year
costs
Support for faculty salary will not be
provided but the percent effort that
the PI and other personnel will
spend on the project should be
stated in the budget and will be
considered as matching funds
Karen Del Rio
(305) 243-5370
kdelrio@.miami.edu
Up to 1 year
costs
Karen Del Rio
(305) 243-5370
kdelrio@miami.edu
Page 48 of 49
Emergency Equipment Grants
"http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir
=asc&fo_page=1&fo_search=1&item=22&p=43&pid=160&
m=fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo
_isls=A*"
About
Emergency Equipment Grants provide support to replace or
repair intensively used equipment that unexpectedly breaks
down or to upgrade existing equipment. These grants are
not intended to cover routine or anticipated repair,
maintenance, or service contracts. All full time faculty at the
Miller School of Medicine are eligible. Applications are due
on the 18th of each month (July – March).
Period of Support
Funds/Direct Costs
Program Contact
Up to 1 year
costs
Karen Del Rio
(305) 243-5370
kdelrio@med.miami.edu
University of Miami Miller School of Medicine
Dean's NIH Bridge Program
"http://uresearch.miami.edu/?p=169&s=33#med"
About
University of Miami Miller School faculty will likely need
additional application cycles in order to successfully obtain
new NIH awards and competitive renewals. These gaps in
funding may put research programs at risk, many of which
have taken significant resources and years to build. In
order to maintain the continuity of our outstanding research
programs, a pool of resources is available to sustain
research that is competitive for NIH funding. These funds
are available for up to one year while new or renewed
support is pursued.
Period of Support
Funds/Direct Costs
Program Contact
Up to 1 year
Up to 50% of the recommended 1st
year Direct Cost budget (excluding
faculty salaries)
Karen Del Rio
(305) 243-5370
kdelrio@med.miami.edu
Page 49 of 49

FUNDING NEWSLETTER APRIL 2014 NIH NOTICES

Transcription

Similar documents

DeFuniak Herald 1-B, 9_19_13

Federal Policy Agenda 1-21-10

NIH to balance sex in cell and animal studies

access granted

Wood-Ridge Foundation

Funding News February 14, 2007

- SoBran, Inc.

SBIR accounting system webinar

EGrAMS Brochure web - HTC Global Services

Funding Opportunities Announcement & Upcoming Deadlines Announcements National Institutes of Health